Antibodies specifically recognizing masp2 and uses thereof

Abstract

Provided are antibodies or antigen-binding fragments that specifically recognize MASP2, and methods of making and uses thereof.

Description

[0001] Cross-references to related applications

[0002] This application claims priority to Chinese Patent Application No. 202111502635.8, filed on December 10, 2021, entitled "Antibody that specifically recognizes MASP2 and its application", the entire contents of which are incorporated herein by reference.

[0003] Reference to the electronic sequence list

[0004] The contents of the electronic sequence list (text name: CN_202112093252_SEQLIST.xml, record date: 2022.08.04, size: 80KB) are incorporated herein by reference in their entirety. Technical Field

[0005] This application relates to antibodies or antigen-binding fragments that specifically recognize MASP2, their preparation methods, and uses. Background Technology

[0006] The complement system is a major branch of the immune response, interacting with multiple immune mechanisms in both innate and adaptive immunity. It is primarily activated via a cascade of three distinct pathways: the classical pathway (CP), the lectin pathway (LP), or the alternative pathway (AP). While each pathway has different initiating factors and unique, specific factors, they all involve the activation of C3 and C5, leading to a common pathway: the formation of the membrane attack complex (MAC, C5b-9), which binds to the target cell membrane, resulting in cell lysis. Unique factors associated with LP activation include collagen lectins (mannose-binding lectins, collagen lectin-10, collagen lectin-11), fibrinogens (fibrinogen 1, fibrinogen 2, fibrinogen 3), and proteins from the mannose-binding lectin-associated serine proteases (MASP) family (MASP-1, MASP-2, MASP-3, MAp19, MAp44). Mannose-binding lectins, collagen lectins, and fibrinogens are all pattern recognition molecules (PRMs) that react with pathogen-associated pattern molecules (PAMPs) or damage-associated pattern molecules (DAMPs). DAMPs include endogenous ligands, such as aberrantly glycosylated host cell surface structures. Although complement activation depends on the direct lysis of pathogens / abnormal self-cells, these factors can function as opsonins, thereby contributing to phagocytosis (Cedzyński, Maciej, and Anna S). Cancers vol.12,7 1792.4Jul.2020).

[0007] The dimers, trimers, and / or higher oligomers of these PRMs trimeric subunits form complexes with the homodimers of MASPs, where the homodimers of MASPs initially exist as enzyme precursors (zymogens) (Kjaer, Troels R et al. Molecular immunology vol. 56, 4(2013): 413-22). Upon binding to their targets, the PRMs cleave and activate the MASPs (Dahl, MR et al. Immunity vol. 15, 1(2001): 127-35; Degn, E etal. Journal of immunology (Baltimore, Md.: 1950) vol. 183, 11 (2009): 7371-8.; Héja, Dávid et al. Proceedings of the National Academy of Sciences of the United States of America vol. 109, 26 (2012): 10498-503.). Although MASP-2 can be self-activated and has long been considered a central activator of the lectin pathway (Ambrus, Géza et al. Journal of Immunology (Baltimore, Md.: 1950) vol. 170, 3(2003): 1374-82.; Gál, Péter et al. The Journal of Biological Chemistry vol. 280, 39(2005): 33435-44.; Matsushita, M et al. Journal of Immunology (Baltimore, Md.: 1950) vol. 165, 5(2000): 2637-42), recent evidence from different authors suggests that MASP-1 can also be self-activated and plays an important role in activating MASP-2 (Degn, E etal. Journal of immunology (Baltimore, Md.: 1950) vol. 189, 8 (2012): 3957-69.; Héja, Dávid et al. Proceedings of the National Academy of Sciences of the United States of America vol. 109, 26 (2012): 10498-503.; Kjaer, Troels R et al. al. Molecularimmunology vol.56,4(2013):413-22.).

[0008] Activated MASP-2 can cleave complement components C4 and C2, producing the C3 convertase C4bC2a. MASP-1 can also cleave C2. The C3 convertase cleaves C3 into C3b, amplifying the cascade reaction and mediating phagocytosis and adaptive immune responses. Adding additional C3b molecules to the C3 convertase forms the C5 convertase (C4bC2aC3b). C3b acts as a binding site for C5, initiating the assembly of the attack complex (MAC) by cleaving C5 into C5a and C5b. C5a is a potent anaphylatoxin, while C5b forms a complex with C6 and C7 and inserts into the cell membrane. Subsequently, C8 and 10–18 C9 molecules bind to this complex, forming a fully functional MAC (C5b-9), ultimately leading to cell lysis and death (Beltrame, Marcia H et al. Molecular Immunology vol.67,1(2015):85-100). In addition, it can activate prothrombin, thereby participating in the activation of the coagulation system (Garred, Peter et al. Immunological reviews vol.274,1(2016):74-97.).

[0009] Several groundbreaking findings have shown that MASP2 is important not only in the activation of the lectin pathway, but also in the formation of fibrin clots in the coagulation cascade. MASP-2 levels are also associated with many diseases, including schizophrenia (Mayilyan, Karine R et al. Neuroscience letters vol.404,3(2006):336-41), septic shock (Charchaflieh, Jean et al. Clinical & developmental immunology vol.2012(2012):407324.), acute lymphoblastic leukemia, non-Hodgkin's lymphoma, central nervous system tumors (Fisch, Urs P et al. Swiss medical weekly vol.141w13191.29Apr.2011.), and colorectal cancer (Ytting, Henriette et al. Clinical cancer research: an official journal of the American Association for Cancer Research vol.11,4(2005):1441-6.; Ytting, Henriette et al. Human immunology MASP2 has been linked to various diseases, including thrombotic microangiopathy (Elhadad, S et al. Clinical and experimental immunology vol.203, 1(2021):96-104), systemic lupus erythematosus (Xu, Wang-Dong et al. Journal of cellular and molecular medicine vol.24, 18(2020):10432-10443), IgA nephropathy (Lafayette, Richard A et al. Kidney international reports vol.5, 11 2032-2041.13Aug.2020), and COVID-19 (Rambaldi, Alessandro et al. Immunobiology vol.225, 6(2020):152001). Therefore, developing inhibitors targeting MASP2 is crucial.

[0010] Currently, antibodies targeting MASP2 have been reported. For example, Chinese patent CN103687620B discloses the anti-MASP2 antibody OMS721 (used as a control antibody in the examples section of this application) and its applications. High-affinity, highly bioactive anti-MASP2 antibodies remain in demand in existing therapeutic areas.

[0011] All publications, patents, patent applications, and disclosed information in published patent applications mentioned herein are incorporated herein by reference in their entirety.

[0012] Application Overview

[0013] In some embodiments, an isolated anti-MASP2 antibody is provided, comprising: a heavy chain variable domain (V H ), the V H Includes: a heavy chain complementarity determination region (HC-CDR)1 containing SDYAWN (SEQ ID NO:1); HC-CDR2 containing YISYSGRTSYNPSLKS (SEQ ID NO:5); and HC-CDR3 containing HYGX1X2 (SEQ ID NO:38), where X1 is D or S and X2 is H or Y; and a light chain variable structural domain (V L ), the V L It includes: a light chain complementarity determination region (LC-CDR)1, which includes KASQNVGTNVA (SEQ ID NO:19); LC-CDR2, which includes SASYRYS (SEQ ID NO:26); and LC-CDR3, which includes X1QYNSX2X3X4 (SEQ ID NO:39), wherein X1 is H or Q, X2 is N or Y, X3 is L or P, and X4 is L or T.

[0014] In some embodiments, an isolated anti-MASP2 antibody is provided, comprising: V H The V H Contains: HC-CDR1, which contains the amino acid sequence shown in SEQ ID NO:1; HC-CDR2, which contains the amino acid sequence shown in SEQ ID NO:5; and HC-CDR3, which contains the amino acid sequence shown in any of SEQ ID NOs:13-14 or a variant thereof, said variant containing substitutions of up to about 3 amino acids; and V L The V LIt comprises: LC-CDR1, which comprises the amino acid sequence shown in SEQ ID NO:19; LC-CDR2, which comprises the amino acid sequence shown in SEQ ID NO:26; and LC-CDR3, which comprises any of the amino acid sequences shown in SEQ ID NOs:30-31 or variants thereof, the variants comprising substitutions of up to about 3 amino acids.

[0015] In some embodiments, an isolated anti-MASP2 antibody is provided, comprising: V H The V H V containing any amino acid sequence as shown in SEQ ID NOs:40 or 44 H Includes HC-CDR1, HC-CDR2, and HC-CDR3, as well as V L The V L V containing any amino acid sequence as shown in SEQ ID NOs:62 or 65 L It includes LC-CDR1, LC-CDR2 and LC-CDR3.

[0016] In some embodiments, an isolated anti-MASP2 antibody is provided, comprising: (i) V H It contains V as shown in the amino acid sequence SEQ ID NO:40. H Includes HC-CDR1, HC-CDR2, and HC-CDR3; and V L It contains V as shown in the amino acid sequence SEQ ID NO:62. L Includes LC-CDR1, LC-CDR2 and LC-CDR3; or (ii)V H It contains V as shown in the amino acid sequence SEQ ID NO:44. H Includes HC-CDR1, HC-CDR2, and HC-CDR3; and V L It contains V as shown in the amino acid sequence SEQ ID NO:65. L It includes LC-CDR1, LC-CDR2 and LC-CDR3.

[0017] In some embodiments, an isolated anti-MASP2 antibody is provided, comprising: (i) V H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO:1; HC-CDR2, which contains the amino acid sequence SEQ ID NO:5; and HC-CDR3, which contains the amino acid sequence SEQ ID NO:13, or the V H Variants of which contain up to about 5 amino acid substitutions in their HC-CDRs; and VL The V L Contains: LC-CDR1, which contains the amino acid sequence SEQ ID NO:19; LC-CDR2, which contains the amino acid sequence SEQ ID NO:26; and LC-CDR3, which contains the amino acid sequence SEQ ID NO:30, or the V L Variants whose LC-CDRs contain substitutions of up to about 5 amino acids; or (ii) V H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO:1; HC-CDR2, which contains the amino acid sequence SEQ ID NO:5; and HC-CDR3, which contains the amino acid sequence SEQ ID NO:14, or the V H Variants of which contain up to about 5 amino acid substitutions in their HC-CDRs; and V L The V L Contains: LC-CDR1, which contains the amino acid sequence SEQ ID NO:19; LC-CDR2, which contains the amino acid sequence SEQ ID NO:26; and LC-CDR3, which contains the amino acid sequence SEQ ID NO:31, or the V L Variants of which contain up to about 5 amino acid substitutions in their LC-CDRs.

[0018] In some embodiments, any isolated anti-MASP2 antibody as described above comprises: V H It comprises any of the amino acid sequences shown in SEQ ID NOs:40-47 or variants thereof, wherein the variants have at least about 80% sequence identity with any of the amino acid sequences shown in SEQ ID NOs:40-47; and V L It comprises any of the amino acid sequences shown in SEQ ID NOs:62-68 or variants thereof, wherein the variants have at least about 80% sequence identity with any of the amino acid sequences shown in SEQ ID NOs:62-68.

[0019] In some embodiments, an isolated anti-MASP2 antibody comprises: (i) V H It comprises the amino acid sequence SEQ ID NO:40 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:40; and V L It contains the amino acid sequence SEQ ID NO:62 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:62; (ii) V HIt comprises the amino acid sequence SEQ ID NO:41 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:41; and V L It contains the amino acid sequence SEQ ID NO:63 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:63; (iii) V H It comprises the amino acid sequence SEQ ID NO:41 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:41; and V L It contains the amino acid sequence SEQ ID NO:64 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:64; (iv)V H It comprises the amino acid sequence SEQ ID NO:42 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:42; and V L It contains the amino acid sequence SEQ ID NO:63 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:63; (v)V H It comprises the amino acid sequence SEQ ID NO:42 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:42; and V L It contains the amino acid sequence SEQ ID NO:64 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:64; (vi)V H It comprises the amino acid sequence SEQ ID NO:43 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:43; and V L It contains the amino acid sequence SEQ ID NO:63 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:63; (vii)V H It comprises the amino acid sequence SEQ ID NO:43 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:43; and V L It contains the amino acid sequence SEQ ID NO:64 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:64; (viii)V HIt comprises the amino acid sequence SEQ ID NO:44 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:44; and V L It contains the amino acid sequence SEQ ID NO:65 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:65; (ix)V H It comprises the amino acid sequence SEQ ID NO:45 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:45; and V L It contains the amino acid sequence SEQ ID NO:66 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:66; (x)V H It comprises the amino acid sequence SEQ ID NO:46 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:46; and V L It contains the amino acid sequence SEQ ID NO:66 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:66; (xi)V H It comprises the amino acid sequence SEQ ID NO:47 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:47; and V L It contains the amino acid sequence SEQ ID NO:66 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:66; (xii)V H It comprises the amino acid sequence SEQ ID NO:45 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:45; and V L It contains the amino acid sequence SEQ ID NO:67 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:67; (xiii)V H It comprises the amino acid sequence SEQ ID NO:46 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:46; and V L It contains the amino acid sequence SEQ ID NO:67 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:67; (xiv)V HIt comprises the amino acid sequence SEQ ID NO:47 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:47; and V L It contains the amino acid sequence SEQ ID NO:67 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:67; (xv)V H It comprises the amino acid sequence SEQ ID NO:45 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:45; and V L It contains the amino acid sequence SEQ ID NO:68 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:68; (xvi)V H It comprises the amino acid sequence SEQ ID NO:46 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:46; and V L It contains the amino acid sequence SEQ ID NO:68 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:68; or (xvii)V H It comprises the amino acid sequence SEQ ID NO:47 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:47; and V L It contains the amino acid sequence SEQ ID NO:68 or a variant thereof, the variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:68.

[0020] In some embodiments, an isolated anti-MASP2 antibody is provided, comprising: (i) V H It contains V as shown in the amino acid sequence SEQ ID NO:48. H Includes HC-CDR1, HC-CDR2, and HC-CDR3; and V L It contains V as shown in the amino acid sequence SEQ ID NO:69. L Includes LC-CDR1, LC-CDR2 and LC-CDR3; (ii)V H It contains V as shown in the amino acid sequence SEQ ID NO:49. H Includes HC-CDR1, HC-CDR2, and HC-CDR3; and V L It contains V as shown in the amino acid sequence SEQ ID NO:70. LIncludes LC-CDR1, LC-CDR2 and LC-CDR3; (iii)V H It contains V as shown in the amino acid sequence SEQ ID NO:50. H Includes HC-CDR1, HC-CDR2, and HC-CDR3; and V L It contains V as shown in the amino acid sequence SEQ ID NO:71. L Includes LC-CDR1, LC-CDR2 and LC-CDR3; (iv)V H It contains V as shown in the amino acid sequence SEQ ID NO:51. H Includes HC-CDR1, HC-CDR2, and HC-CDR3; and V L It contains V as shown in the amino acid sequence SEQ ID NO:72. L Includes LC-CDR1, LC-CDR2 and LC-CDR3; (v)V H It contains V as shown in the amino acid sequence SEQ ID NO:52. H Includes HC-CDR1, HC-CDR2, and HC-CDR3; and V L It contains V as shown in the amino acid sequence SEQ ID NO:73. L Includes LC-CDR1, LC-CDR2 and LC-CDR3; (vi)V H It contains V as shown in the amino acid sequence SEQ ID NO:53. H Includes HC-CDR1, HC-CDR2, and HC-CDR3; and V L It contains V as shown in the amino acid sequence SEQ ID NO:72. L Includes LC-CDR1, LC-CDR2 and LC-CDR3; (vii)V H It contains V as shown in the amino acid sequence SEQ ID NO:54. H Includes HC-CDR1, HC-CDR2, and HC-CDR3; and V L It contains V as shown in the amino acid sequence SEQ ID NO:74. L Includes LC-CDR1, LC-CDR2 and LC-CDR3; or (viii)V H It contains V as shown in the amino acid sequence SEQ ID NO:55. H Includes HC-CDR1, HC-CDR2, and HC-CDR3; and V L It contains V as shown in the amino acid sequence SEQ ID NO:75. LIt includes LC-CDR1, LC-CDR2 and LC-CDR3.

[0021] In some embodiments, an isolated anti-MASP2 antibody is provided, comprising: (i) V H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO:2; HC-CDR2, which contains the amino acid sequence SEQ ID NO:6; and HC-CDR3, which contains the amino acid sequence SEQ ID NO:15, or the V H Variants of which contain up to about 5 amino acid substitutions in their HC-CDRs; and V L The V L Contains: LC-CDR1, which contains the amino acid sequence SEQ ID NO:20; LC-CDR2, which contains the amino acid sequence SEQ ID NO:27; and LC-CDR3, which contains the amino acid sequence SEQ ID NO:32, or the V L (ii) V variants, whose LC-CDRs contain substitutions of up to about 5 amino acids; H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO:2; HC-CDR2, which contains the amino acid sequence SEQ ID NO:7; and HC-CDR3, which contains the amino acid sequence SEQ ID NO:16, or the V H Variants of which contain up to about 5 amino acid substitutions in their HC-CDRs; and V L The V L Contains: LC-CDR1, which contains the amino acid sequence SEQ ID NO:21; LC-CDR2, which contains the amino acid sequence SEQ ID NO:27; and LC-CDR3, which contains the amino acid sequence SEQ ID NO:33, or the V L (iii) V variants, whose LC-CDRs contain substitutions of up to about 5 amino acids; H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO:1; HC-CDR2, which contains the amino acid sequence SEQ ID NO:5; and HC-CDR3, which contains the amino acid sequence SEQ ID NO:17, or the V H Variants of which contain up to about 5 amino acid substitutions in their HC-CDRs; and V L The V LContains: LC-CDR1, which contains the amino acid sequence SEQ ID NO:19; LC-CDR2, which contains the amino acid sequence SEQ ID NO:26; and LC-CDR3, which contains the amino acid sequence SEQ ID NO:31, or the V L (iv) V variants, whose LC-CDRs contain substitutions of up to about 5 amino acids; H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO:3; HC-CDR2, which contains the amino acid sequence SEQ ID NO:8; and HC-CDR3, which contains the amino acid sequence SEQ ID NO:18, or the V H Variants of which contain up to about 5 amino acid substitutions in their HC-CDRs; and V L The V L Contains: LC-CDR1, which contains the amino acid sequence SEQ ID NO:22; LC-CDR2, which contains the amino acid sequence SEQ ID NO:28; and LC-CDR3, which contains the amino acid sequence SEQ ID NO:34, or the V L The variants, whose LC-CDRs contain substitutions of up to about 5 amino acids; (v)V H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO:3; HC-CDR2, which contains the amino acid sequence SEQ ID NO:9; and HC-CDR3, which contains the amino acid sequence SEQ ID NO:18, or the V H Variants of which contain up to about 5 amino acid substitutions in their HC-CDRs; and V L The V L Contains: LC-CDR1, which contains the amino acid sequence SEQ ID NO:23; LC-CDR2, which contains the amino acid sequence SEQ ID NO:29; and LC-CDR3, which contains the amino acid sequence SEQ ID NO:35, or the V L The variants, whose LC-CDRs contain substitutions of up to about 5 amino acids; (vi)V H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO:3; HC-CDR2, which contains the amino acid sequence SEQ ID NO:10; and HC-CDR3, which contains the amino acid sequence SEQ ID NO:18, or the V H Variants of which contain up to about 5 amino acid substitutions in their HC-CDRs; and V L The VL Contains: LC-CDR1, which contains the amino acid sequence SEQ ID NO:22; LC-CDR2, which contains the amino acid sequence SEQ ID NO:28; and LC-CDR3, which contains the amino acid sequence SEQ ID NO:34, or the V L The variants, whose LC-CDRs contain substitutions of up to about 5 amino acids; (vii)V H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO:4; HC-CDR2, which contains the amino acid sequence SEQ ID NO:11; and HC-CDR3, which contains the amino acid sequence SEQ ID NO:18, or the V H Variants of which contain up to about 5 amino acid substitutions in their HC-CDRs; and V L The V L Contains: LC-CDR1, which contains the amino acid sequence SEQ ID NO:24; LC-CDR2, which contains the amino acid sequence SEQ ID NO:28; and LC-CDR3, which contains the amino acid sequence SEQ ID NO:34, or the V L Variants of which contain substitutions of up to about 5 amino acids in their LC-CDRs; or (viii)V H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO:3; HC-CDR2, which contains the amino acid sequence SEQ ID NO:12; and HC-CDR3, which contains the amino acid sequence SEQ ID NO:18, or the V H Variants of which contain up to about 5 amino acid substitutions in their HC-CDRs; and V L The V L Contains: LC-CDR1, which contains the amino acid sequence SEQ ID NO:23; LC-CDR2, which contains the amino acid sequence SEQ ID NO:28; and LC-CDR3, which contains the amino acid sequence SEQ ID NO:36, or the V L Variants of which contain up to about 5 amino acid substitutions in their LC-CDRs.

[0022] In some embodiments, any of the isolated anti-MASP2 antibodies described above comprises: (i) V H It comprises the amino acid sequence shown in SEQ ID NO:48 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO:48; and V LIt comprises the amino acid sequence shown in SEQ ID NO:69 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO:69; (ii) V H It comprises the amino acid sequence shown in SEQ ID NO:49 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO:49; and V L It comprises the amino acid sequence shown in SEQ ID NO:70 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO:70; (iii) V H It comprises the amino acid sequence shown in SEQ ID NO:50 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO:50; and V L It comprises the amino acid sequence shown in SEQ ID NO:71 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO:71; (iv) V H It comprises the amino acid sequence shown in SEQ ID NO:51 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO:51; and V L It comprises the amino acid sequence shown in SEQ ID NO:72 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO:72; (v)V H It comprises the amino acid sequence shown in SEQ ID NO:52 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO:52; and V L It comprises the amino acid sequence shown in SEQ ID NO:73 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO:73; (vi)V H It comprises the amino acid sequence shown in SEQ ID NO:53 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO:53; and V L It comprises the amino acid sequence shown in SEQ ID NO:72 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO:72; (vii)V HIt comprises the amino acid sequence shown in SEQ ID NO:54 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO:54; and V L It comprises the amino acid sequence shown in SEQ ID NO:74 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO:74; or (viii)V H It comprises the amino acid sequence shown in SEQ ID NO:55 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO:55; and V L It contains the amino acid sequence shown in SEQ ID NO:75 or a variant thereof, the variant having at least about 80% sequence identity with the amino acid sequence shown in SEQ ID NO:75.

[0023] In some embodiments, an isolated anti-MASP2 antibody is provided, comprising: V H It contains V as shown in the amino acid sequence SEQ ID NO:56. H Includes HC-CDR1, HC-CDR2, and HC-CDR3; and V L It contains V as shown in the amino acid sequence SEQ ID NO:76. L It includes LC-CDR1, LC-CDR2 and LC-CDR3.

[0024] In some embodiments, an isolated anti-MASP2 antibody is provided, comprising: V H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO:3; HC-CDR2, which contains the amino acid sequence SEQ ID NO:10; and HC-CDR3, which contains the amino acid sequence SEQ ID NO:18, or the V H Variants of which contain up to about 5 amino acid substitutions in their HC-CDRs; and V L The V L Contains: LC-CDR1, which contains the amino acid sequence SEQ ID NO:25; LC-CDR2, which contains the amino acid sequence SEQ ID NO:28; and LC-CDR3, which contains the amino acid sequence SEQ ID NO:37, or the V L Variants of which contain up to about 5 amino acid substitutions in their LC-CDRs.

[0025] In some embodiments, any of the isolated anti-MASP2 antibodies described above comprises: (i) VH It comprises the amino acid sequence SEQ ID NO:56 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:56; and V L It contains the amino acid sequence SEQ ID NO:76 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:76; (ii) V H It comprises the amino acid sequence SEQ ID NO:57 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:57; and V L It contains the amino acid sequence SEQ ID NO:77 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:77; (iii) V H It comprises the amino acid sequence SEQ ID NO:58 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:58; and V L It contains the amino acid sequence SEQ ID NO:77 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:77; (iv) V H It comprises the amino acid sequence SEQ ID NO:59 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:59; and V L It contains the amino acid sequence SEQ ID NO:77 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:77; (v)V H It comprises the amino acid sequence SEQ ID NO:60 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:60; and V L It contains the amino acid sequence SEQ ID NO:77 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:77; (vi)V H It comprises the amino acid sequence SEQ ID NO:61 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:61; and V L It contains the amino acid sequence SEQ ID NO:77 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:77; (vii)V HIt comprises the amino acid sequence SEQ ID NO:57 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:57; and V L It contains the amino acid sequence SEQ ID NO:78 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:78; (viii)V H It comprises the amino acid sequence SEQ ID NO:58 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:58; and V L It contains the amino acid sequence SEQ ID NO:78 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:78; (ix)V H It comprises the amino acid sequence SEQ ID NO:59 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:59; and V L It contains the amino acid sequence SEQ ID NO:78 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:78; (x)V H It comprises the amino acid sequence SEQ ID NO:60 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:60; and V L It contains the amino acid sequence SEQ ID NO:78 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:78; (xi)V H It comprises the amino acid sequence SEQ ID NO:61 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:61; and V L It contains the amino acid sequence SEQ ID NO:78 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:78; (xii)V H It comprises the amino acid sequence SEQ ID NO:57 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:57; and V L It contains the amino acid sequence SEQ ID NO:79 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:79; (xiii)V HIt comprises the amino acid sequence SEQ ID NO:58 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:58; and V L It contains the amino acid sequence SEQ ID NO:79 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:79; (xiv)V H It comprises the amino acid sequence SEQ ID NO:59 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:59; and V L It contains the amino acid sequence SEQ ID NO:79 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:79; (xv)V H It comprises the amino acid sequence SEQ ID NO:60 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:60; and V L It contains the amino acid sequence SEQ ID NO:79 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:79; or (xvi)V H It comprises the amino acid sequence SEQ ID NO:61 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:61; and V L It contains the amino acid sequence SEQ ID NO:79 or a variant thereof, the variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:79.

[0026] In some embodiments, the Kd value of the isolated anti-MASP2 antibody binding to human MASP2 is 1 pM to 10 nM.

[0027] In some embodiments, an isolated anti-MASP2 antibody is provided that competes with any of the isolated anti-MASP2 antibodies described above for specific binding to MASP2. In some embodiments, an isolated anti-MASP2 antibody is provided that specifically binds to the same epitope as any of the isolated anti-MASP2 antibodies described above.

[0028] In some embodiments, the isolated anti-MASP2 antibody, as described above, comprises an Fc fragment. In some embodiments, the isolated anti-MASP2 antibody is a full-length IgG antibody. In some embodiments, the isolated anti-MASP2 antibody is a full-length IgG1 or IgG4 antibody. In some embodiments, the isolated anti-MASP2 antibody is a chimeric, fully human, or humanized antibody. In some embodiments, the isolated anti-MASP2 antibody is an antigen-binding fragment selected from the group consisting of Fab, Fab', F(ab)'2, Fab'-SH, single-chain Fv (scFv), Fv fragments, dAb, Fd, nanobody, diabody, and linear antibody.

[0029] In some embodiments, an isolated nucleic acid molecule is provided, the nucleic acid molecule encoding any of the anti-MASP2 antibodies described above. In some embodiments, a vector is provided, the vector comprising any of the nucleic acid molecules described above. In some embodiments, a host cell is provided, the host cell comprising any of the anti-MASP2 antibodies described above, any of the nucleic acid molecules described above, or any of the vectors described above. In some embodiments, a method for preparing an anti-MASP2 antibody is provided, comprising: a) culturing any of the above-described host cells under conditions that enable efficient expression of the anti-MASP2 antibody; and b) obtaining the expressed anti-MASP2 antibody from the host cell.

[0030] In some embodiments, a method of treating a desired individual disease or condition is provided, comprising administering an effective amount of any of the anti-MASP2 antibodies described above to the individual. In some embodiments, the use of any of the anti-MASP2 antibodies described above in the preparation of a pharmaceutical composition for treating a desired individual disease or condition is provided. In some embodiments, the use of any of the anti-MASP2 antibodies described above or a pharmaceutical composition comprising an anti-MASP2 antibody in the preparation of a medicament for treating a disease or condition is provided. In some embodiments, the disease or condition is related to MASP2-dependent complement activation, including autoimmune diseases, inflammatory diseases, blood disorders, coagulation disorders, angiogenesis-dependent diseases, and / or viral infectious diseases or conditions. In some embodiments, the disease or condition is selected from, for example, ischemia-reperfusion injury, atherosclerosis, mesangial proliferative glomerulonephritis, membranous glomerulonephritis, membranoproliferative glomerulonephritis, acute post-infectious glomerulonephritis, cryoglobulinemia glomerulonephritis, lupus nephritis, Henoch-Schönlein purpura nephritis, IgA nephropathy, severe sepsis, septic shock, acute respiratory distress syndrome or systemic inflammatory response syndrome caused by sepsis, hemorrhagic shock, hemolytic anemia, autoimmune thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), atypical thrombocytopenic purpura, etc. Hematuria-associated uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), transplant-associated mesotherapy-associated tachycardia (TA-TMA), Upshaw-Schulman syndrome, catastrophic antiphospholipid syndrome (CAPS), Degos disease, disseminated intravascular coagulation (DIC), angiogenesis-dependent cancer, age-related macular degeneration, proliferative diabetic retinopathy, proliferative diabetic retinopathy with secondary vitreous hemorrhage, neovascular glaucoma, corneal neovascularization, retinopathy of prematurity, and respiratory distress syndrome or pneumonia caused by coronavirus infection, etc.

[0031] It also provides pharmaceutical compositions, kits, and manufactured products containing any of the anti-MASP2 antibodies described above. Attached Figure Description

[0032] Figure 1 The results show that the anti-MASP2 antibodies humM2mc51-1 and humM2mc67-9 inhibited the activity of C4b deposition in monkey serum.

[0033] Figure 2 The results shown are the trends of plasma drug concentrations of anti-MASP2 antibodies humM2mc12-1, humM2mc51-1, and humM2mc67-9 over time.

[0034] Figures 3A-3CThe results show that the anti-MASP2 antibodies humM2mc67 and humM2mc51-1 inhibited C4b in cynomolgus monkeys. Figure 3A C3b Figure 3B ) and MAC Figure 3C The formation of ).

[0035] Detailed description of this application

[0036] This application provides an anti-MASP2 antibody molecule. Through screening a scFv phage library, a combination of appropriately designed biochemical and biological experiments, and antibody humanization, a highly efficient antibody molecule capable of binding to human MASP2 and inhibiting MASP2-dependent complement lectin pathway activation has been identified. The results presented herein demonstrate that the antibody in this application more effectively inhibits complement lectin pathway activation compared to known anti-MASP2 antibodies.

[0037] The anti-MASP2 antibodies provided in this application include, for example, full-length anti-MASP2 antibodies, anti-MASP2 single-chain antibodies (scFvs), anti-MASP2 Fc fusion proteins, multispecific (e.g., bispecific) anti-MASP2 antibodies, anti-MASP2 immunoconjugates, and the like.

[0038] On the other hand, this application provides an anti-MASP2 antibody, which comprises: a heavy chain variable domain (V H ), the V H Includes: a heavy chain complementarity determination region (HC-CDR)1 containing SDYAWN (SEQ ID NO:1); HC-CDR2 containing YISYSGRTSYNPSLKS (SEQ ID NO:5); and HC-CDR3 containing HYGX1X2 (SEQ ID NO:38), where X1 is D or S and X2 is H or Y; and a light chain variable structural domain (V L ), the V L It includes: a light chain complementarity determination region (LC-CDR)1, which includes KASQNVGTNVA (SEQ ID NO:19); LC-CDR2, which includes SASYRYS (SEQ ID NO:26); and LC-CDR3, which includes X1QYNSX2X3X4 (SEQ ID NO:39), wherein X1 is H or Q, X2 is N or Y, X3 is L or P, and X4 is L or T.

[0039] On the other hand, this application provides an anti-MASP2 antibody, which comprises: a heavy chain variable domain (V H ), the V HIncludes: heavy chain complementarity-determining region (HC-CDR)1, which contains SFWMH (SEQ ID NO:2); HC-CDR2, which contains YINPGTGYTDYNQKFKD (SEQ ID NO:6); and HC-CDR3, which contains FYGRRGY (SEQ ID NO:15); and light chain variable structural domain (V L ), the V L It includes: light chain complementarity determination region (LC-CDR)1, which includes SASSVSYMH (SEQ ID NO:20); LC-CDR2, which includes STSNLAS (SEQ ID NO:27); and LC-CDR3, which includes QQRSSYPFT (SEQ ID NO:32).

[0040] On the other hand, this application provides an anti-MASP2 antibody, which comprises: a heavy chain variable domain (V H ), the V H It includes: heavy chain complementarity-determining region (HC-CDR)1, which contains SFWMH (SEQ ID NO:2); HC-CDR2, which contains YINPSTGYTDYNQQFKD (SEQ ID NO:7); and HC-CDR3, which contains FYGRRDY (SEQ ID NO:16); and light chain variable structural domain (V L ), the V L It includes: light chain complementarity determination region (LC-CDR)1, which includes SASSVSSMH (SEQ ID NO:21); LC-CDR2, which includes STSNLAS (SEQ ID NO:27); and LC-CDR3, which includes QQRSNYPFT (SEQ ID NO:33).

[0041] On the other hand, this application provides an anti-MASP2 antibody, which comprises: a heavy chain variable domain (V H ), the V H Includes: heavy chain complementarity determination region (HC-CDR)1, which contains SDYAWN (SEQ ID NO:1); HC-CDR2, which contains YISYSGRTSYNPSLKS (SEQ ID NO:5); and HC-CDR3, which contains IGTLGY (SEQ ID NO:17); and light chain variable structural domain (V L ), the V LIt includes: light chain complementarity determination region (LC-CDR)1, which includes KASQNVGTNVA (SEQ ID NO:19); LC-CDR2, which includes SASYRYS (SEQ ID NO:26); and LC-CDR3, which includes HQYNSNPLT (SEQ ID NO:31).

[0042] On the other hand, this application provides an anti-MASP2 antibody, which comprises: a heavy chain variable domain (V H ), the V H Includes: heavy chain complementarity-determining region (HC-CDR)1, which contains RFGMH (SEQ ID NO:3); HC-CDR2, which contains YISSGGSAIFYADTVKG (SEQ ID NO:8); and HC-CDR3, which contains GDRALDY (SEQ ID NO:18); and light chain variable structural domain (V L ), the V L It includes: light chain complementarity determination region (LC-CDR)1, which contains RASQSVSSSSYSYIH (SEQ ID NO:22); LC-CDR2, which contains HASNLES (SEQ ID NO:28); and LC-CDR3, which contains QHSWESPWT (SEQ ID NO:34).

[0043] On the other hand, this application provides an anti-MASP2 antibody, which comprises: a heavy chain variable domain (V H ), the V H It includes: heavy chain complementarity-determining region (HC-CDR)1, which contains RFGMH (SEQ ID NO:3); HC-CDR2, which contains YISSGGSSIFYADTVKG (SEQ ID NO:9); and HC-CDR3, which contains GDRALDY (SEQ ID NO:18); and light chain variable structural domain (V L ), the V L It includes: light chain complementarity determination region (LC-CDR)1, which contains RASKSVSTSGYSYIH (SEQ ID NO:23); LC-CDR2, which contains YASNLES (SEQ ID NO:29); and LC-CDR3, which contains QHSWEAPWT (SEQ ID NO:35).

[0044] On the other hand, this application provides an anti-MASP2 antibody, which comprises: a heavy chain variable domain (V H ), the V HIncludes: heavy chain complementarity-determining region (HC-CDR)1, which contains RFGMH (SEQ ID NO:3); HC-CDR2, which contains YISSGSSAVFYADTVKG (SEQ ID NO:10); and HC-CDR3, which contains GDRALDY (SEQ ID NO:18); and light chain variable structural domain (V L ), the V L It includes: light chain complementarity determination region (LC-CDR)1, which contains RASQSVSSSSYSYIH (SEQ ID NO:22); LC-CDR2, which contains HASNLES (SEQ ID NO:28); and LC-CDR3, which contains QHSWESPWT (SEQ ID NO:34).

[0045] On the other hand, this application provides an anti-MASP2 antibody, which comprises: a heavy chain variable domain (V H ), the V H It includes: heavy chain complementarity-determining region (HC-CDR)1, which contains SFGMH (SEQ ID NO:4); HC-CDR2, which contains YISSGSRSVFYADTVKG (SEQ ID NO:11); and HC-CDR3, which contains GDRALDY (SEQ ID NO:18); and light chain variable structural domain (V L ), the V L It includes: light chain complementarity determination region (LC-CDR)1, which contains RASQSVSSSSYGYIH (SEQ ID NO:24); LC-CDR2, which contains HASNLES (SEQ ID NO:28); and LC-CDR3, which contains QHSWESPWT (SEQ ID NO:34).

[0046] On the other hand, this application provides an anti-MASP2 antibody, which comprises: a heavy chain variable domain (V H ), the V H Includes: heavy chain complementarity-determining region (HC-CDR)1, which contains RFGMH (SEQ ID NO:3); HC-CDR2, which contains YISSGSSSIFYADTVKG (SEQ ID NO:12); and HC-CDR3, which contains GDRALDY (SEQ ID NO:18); and light chain variable structural domain (V L ), the V LIt includes: light chain complementarity determination region (LC-CDR)1, which contains RASKSVSTSGYSYIH (SEQ ID NO:23); LC-CDR2, which contains HASNLES (SEQ ID NO:28); and LC-CDR3, which contains LHSWESPWT (SEQ ID NO:36).

[0047] On the other hand, this application provides an anti-MASP2 antibody, which comprises: a heavy chain variable domain (V H ), the V H Includes: heavy chain complementarity-determining region (HC-CDR)1, which contains RFGMH (SEQ ID NO:3); HC-CDR2, which contains YISSGSSAVFYADTVKG (SEQ ID NO:10); and HC-CDR3, which contains GDRALDY (SEQ ID NO:18); and light chain variable structural domain (V L ), the V L It includes: light chain complementarity determination region (LC-CDR)1, which contains RASQSVSSSRYSYIH (SEQ ID NO:25); LC-CDR2, which contains HASNLES (SEQ ID NO:28); and LC-CDR3, which contains QHSWDTPWT (SEQ ID NO:37).

[0048] It also provides nucleic acids encoding anti-MASP2 antibodies, compositions containing anti-MASP2 antibodies, and methods for preparing and using anti-MASP2 antibodies.

[0049] definition

[0050] As described herein, “treatment” or “treating” is a method of obtaining a beneficial or desired outcome, including clinical outcomes. For the purposes of this application, the beneficial or desired clinical outcome includes, but is not limited to, one or more of the following: relief of one or more symptoms caused by a disease, reduction of disease severity, stabilization of the disease (e.g., prevention or delay of disease exacerbation), prevention or delay of disease spread (e.g., metastasis), prevention or delay of disease recurrence, delay or slowing of disease progression, improvement of disease status, relief of the disease (partial or complete), reduction of the dosage of one or more other medications required to treat the disease, delay of disease progression, improvement or enhancement of quality of life, weight gain, and / or prolongation of survival. Simultaneously, “treatment” also includes reductions in disease pathological outcomes (e.g., reduction of immune complex deposition, inhibition of thrombus formation). The methods of this application consider any one or more aspects of these treatments.

[0051] The term "antibody" includes both full-length antibodies and their antigen-binding fragments. Full-length antibodies consist of two heavy chains and two light chains. Variable regions in both the light and heavy chains are responsible for antigen binding. The variable regions in both chains typically include three hypervariable loops, referred to as complementarity-determining regions (CDRs) (light chain (LC) CDRs include LC-CDR1, LC-CDR2, and LC-CDR3; heavy chain (HC) CDRs include HC-CDR1, HC-CDR2, and HC-CDR3). The CDR boundaries of the antibodies or antigen-binding fragments disclosed herein can be defined or identified according to the Kabat, Chothia, or Al-Lazikani conventions (Al-Lazikani 1997; Chothia 1985; Chothia 1987; Chothia 1989; Kabat 1987; Kabat 1991). Three CDR regions of the heavy or light chain are inserted between flanking segments called framework regions (FRs), which are more conserved than the CDR regions and form a scaffold supporting the hypervariable loop. The constant regions of the heavy and light chains do not participate in antigen binding but exhibit a variety of effector functions. Antibodies are classified based on the amino acid sequence of their heavy chain constant regions. The five main classes or isotypes of antibodies are IgA, IgD, IgE, IgG, and IgM, characterized by having α, δ, ε, γ, and μ-type heavy chains, respectively. Several major antibody classes are subclassed, such as IgG1 (γ1 heavy chain), IgG2 (γ2 heavy chain), IgG3 (γ3 heavy chain), IgG4 (γ4 heavy chain), IgA1 (α1 heavy chain), or IgA2 (α2 heavy chain).

[0052] As described herein, the term "antigen-binding fragment" includes antibody fragments, such as diabody, Fab, Fab', F(ab')2, Fv fragments, disulfide-stabilized Fv fragments (dsFv), (dsFv)2, bispecific dsFv (dsFv-dsFv'), disulfide-stabilized diabody (ds-diabody), single-chain Fv (scFv), scFv dimers (bivalent diabody), multispecific antibodies, single-domain antibodies, nanobodies, domain antibodies, divalent domain antibodies, or any other antibody fragment capable of binding to an antigen but not containing a complete antibody structure. The antigen-binding fragment is capable of binding the same antigen to a parent antibody or a parent antibody fragment (such as a parental scFv). The antigen-binding fragment also includes fusion proteins comprising the antibody fragments described above. In some embodiments, the antigen-binding fragment may include one or more CDRs from a specific human antibody that have been grafted into a frame region from one or more different human antibodies.

[0053] As described herein, the term "epitope" refers to a specific set of atoms or amino acids on an antigen that an antibody or antibody portion binds to. If two antibodies or antibody portions exhibit competitive binding to an antigen, they may bind to the same epitope on the antigen.

[0054] As used herein, when the first antibody inhibits the binding of the second antibody to the MASP2 target by at least 50% (e.g., at least 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%) at an equimolar concentration, the first antibody “competitively” binds to the MASP2 target with the second antibody, and vice versa. PCT Publication WO 03 / 48731 describes a high-throughput antibody “epitope classification” method based on cross-competition.

[0055] As described herein, the terms "specifically bind," "specifically recognize," or "specific to" refer to measurable and reproducible interactions, such as antibody binding to a target that confirms the presence of that target in a heterogeneous group of molecules, including biomolecules. For example, an antibody's ability to specifically recognize a target (which may be an epitope) means that the antibody binds to that target with higher affinity, stronger binding, and / or more persistent binding compared to binding to other targets. In some embodiments, an antibody that specifically recognizes an antigen reacts with one or more antigenic determinants of the antigen with a binding affinity at least 10 times greater than its binding affinity to other targets.

[0056] As described herein, an “isolated” anti-MASP2 antibody is an anti-MASP2 antibody that (1) is not related to a naturally occurring protein, (2) does not contain other proteins of the same origin, (3) is expressed by cells of a different species, or (4) does not exist in nature.

[0057] As described herein, the term “isolated nucleic acid” refers to a nucleic acid or combination thereof of genomic, cDNA, or synthetic origin. Depending on its origin, “isolated nucleic acid” means that it is (1) unrelated to all or part of the polynucleotides in “isolated nucleic acids” found in nature, (2) operablely ligable to polynucleotides not naturally associated with it, or (3) not present in nature as part of a longer sequence.

[0058] As used herein, the term “CDR” or “complementarity-determining region” refers to a discontinuous antigen-binding site found within the variable domains of heavy and light chain polypeptides. In the literature Kabat et al., J. Biol. Chem. 252: 6609-6616 (1977); Kabat et al., USDept. of Health and Human Services, "Sequences of proteins of immunological interest" (1991); Chothia et al., J. Mol. Biol. 196: 901-917 (1987); Al-Lazikani B. et al. al., J. Mol. Biol., 273: 927-948 (1997); MacCallum et al., J. Mol. Biol. 262: 732-745 (1996); Abhinandan and Martin, Mol. Immunol., 45: 3832-3839 (2008); Lefranc MPet These specific regions have been described in al., Dev. Comp. Immunol., 27:55-77 (2003); and Honegger and Plückthun, J. Mol. Biol., 309:657-670 (2001), where these definitions include overlaps or subsets of amino acid residues when compared with each other. However, any definition used to indicate a CDR of an antibody or transplanted antibody or its variants is included within the scope of the terminology defined and used herein. Table 1 lists the positions of the amino acid residues included in the CDRs defined by the aforementioned references for comparison. Algorithms and interfaces for CDR prediction are known in the art, including, for example, those described in Abhinandan and Martin, Mol. Immunol., 45:3832-3839 (2008); Ehrenmann F. et al., Nucleic Acids Res., 38:D301-D307 (2010); and Adolf-Bryfogle J. et al., Nucleic Acids Res., 43:D432-D438 (2015). The entire contents of the references cited in this paragraph are incorporated herein by reference for the purposes of this application and one or more claims that may be included herein.

[0059] Table 1: CDR Definition

[0060] Kabat 1 ]]> Chothia 2 ]]> MacCallum 3 ]]> IMGT 4 ]]> <![CDATA[AHo 5 ]]> <![CDATA[V H CDR1]]> 31-35 26-32 30-35 27-38 25-40 <![CDATA[V H CDR2]]> 50-65 53-55 47-58 56-65 58-77 <![CDATA[V H CDR3]]> 95-102 96-101 93-101 105-117 109-137 <![CDATA[V L CDR1]]> 24-34 26-32 30-36 27-38 25-40 <![CDATA[V L CDR2]]> 50-56 50-52 46-55 56-65 58-77 <![CDATA[V L CDR3]]> 89-97 91-96 89-96 105-117 109-137

[0061] 1 The amino acid residue numbering follows the nomenclature method described in Kabat et al. above.

[0062] 2 The amino acid residue numbering follows the nomenclature method described in Chothia et al. above.

[0063] 3 The amino acid residue numbering follows the nomenclature method described in MacCallum et al. above.

[0064] 4 The amino acid residue numbering follows the nomenclature method described in Lefranc et al. above.

[0065] 5 The amino acid residue numbering follows the nomenclature method described in Honegger and Plückthun.

[0066] The term "chimeric antibody" refers to an antibody in which a portion of the heavy chain and / or light chain is identical or homologous to the corresponding sequence in an antibody from a particular species or belonging to a particular antibody species or subclass, while the remainder of the chain is identical or homologous to the corresponding sequence in an antibody from another genus or belonging to another antibody species or subclass, as well as fragments of such antibodies, provided they possess the biological activity described in this application (see US Patent No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)).

[0067] "Fv" is the smallest antibody fragment containing a complete antigen recognition and binding site. This fragment is a dimer formed by a heavy chain variable domain and a light chain variable domain tightly and non-covalently linked. The folding of these two domains derives six hypervariable rings (three in the light chain and three in the heavy chain), which provide the antibody with amino acid residues for binding to the antigen and confer the antibody's specificity for antigen binding. However, even a single variable domain (or half of the Fv fragment, containing only three antigen-specific CDRs) can recognize and bind to antigens, although its affinity is lower than that of the complete binding site.

[0068] "Single-chain Fv", also abbreviated as "sFv" or "scFv", is a type of Fv containing V molecules linked together to form a single polypeptide chain. H and V L Antibody fragments of antibody domains. In some embodiments, the scFv polypeptide further includes V H and V LThe linker polypeptide between the domains allows scFv to form an ideal structure for antigen binding. For an overview of scFv, see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994).

[0069] The term "diabody" is used in V H and V L Small antibody fragments are prepared by constructing scFv fragments (see above) using short linkers (e.g., 5–10 residues) between domains. This allows the variable domains to pair between chains rather than within chains, resulting in a bivalent fragment, i.e., a fragment with two antigen-binding sites. Bispecific double-chain antibodies are heterodimers of two “crossed” scFv fragments, where the V0 of the two antibodies... H and V L The domains are located on different polypeptide chains. Double-chain antibodies are fully described in EP404,097; WO 93 / 11161; Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993).

[0070] The “humanized” form of non-human (e.g., rodent) antibodies is a chimeric antibody, which includes a minimal sequence derived from the non-human antibody. In most cases, humanized antibodies are human immunoglobulins (receptor antibodies), where the hypervariable region (HVR) residues of the receptor antibody are replaced by hypervariable region residues from non-human species such as mice, rats, rabbits, or non-human mammals that possess desirable antibody specificity, affinity, and performance (donor antibody). In some cases, residues in the human immunoglobulin framework region are replaced by corresponding non-human residues. Additionally, humanized antibodies may include residues not present in either the receptor or donor antibody. These modifications can further improve antibody performance. Typically, humanized antibodies contain substantially all, at least one, and usually two variable domains, where all or substantially all of the hypervariable loops correspond to the hypervariable loops of a non-human immunoglobulin, and all or substantially all of the framework regions are human immunoglobulin sequences. Humanized antibodies may also optionally include at least a portion of the immunoglobulin constant region (Fc), typically the constant region of a human immunoglobulin. For details, please refer to Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992).

[0071] The "percentage of amino acid sequence identity (%)" or "homology" of the peptide and antibody sequences identified in this paper is defined as the percentage of identical amino acid residues in a candidate sequence compared to a peptide sequence, assuming that conserved substitutions are part of sequence identity. The percentage of amino acid sequence identity can be determined using various alignment methods within the scope of the art, such as publicly available computer software like BLAST, BLAST-2, ALIGN, Megalign (DNASTAR), or MUSCLE software. Those skilled in the art can determine suitable parameters for measuring alignment, including any algorithm required to maximize alignment across the full length of the compared sequences. However, for the purposes of this paper, the percentage of amino acid sequence identity values ​​were generated using the sequence alignment computer program MUSCLE (Edgar, RC, Nucleic Acids Research 32(5):1792-1797, 2004; Edgar, RC, BMC Bioinformatics 5(1):113, 2004).

[0072] The term "Fc receptor" or "FcR" is used to describe receptors that bind to the Fc region of antibodies. In some embodiments, the FcR described in this application is an FcR that binds to IgG antibodies (a type of γ receptor), including receptors of the FcγRI, FcγRII, and FcγRIII subclasses, including allelic variants and alternative splicing forms of these receptors. FcγRII receptors include FcγRIIA ("activating receptor") and FcγRIIB ("inhibiting receptor"), which have similar amino acid sequences and differ primarily in their cytoplasmic domains. The cytoplasmic domain of the activating receptor FcγRIIA contains an immunoreceptor tyrosine activation motif (ITAM). The cytoplasmic domain of the inhibitory receptor FcγRIIB contains an immunoreceptor tyrosine inhibitory motif (ITIM) (see M.in.). Annu.Rev.Immunol.15:203-234 (1997)). The term also includes allotypes, such as FcγRIIIA allotypes: FcγRIIIA-Phe158, FcγRIIIA-Val158, FcγRIIA-R131 and / or FcγRIIA-H131. FcRs are described in Ravetch and Kinet, Annu.Rev.Immunol 9:457-92 (1991) and Capel et al., Immunomethods 4:25-34 (1994); and de Haas et al., J.Lab.Clin.Med.126:330-41 (1995). In this application, the term FcR covers other types of FcRs, including those to be identified in the future. The term FcR also includes the neonatal receptor FcRn, which is responsible for transferring maternal IgGs to the newborn (Guyer et al., J. Immunol. 117:587 (1976) and Kim et al., J. Immunol. 24:249 (1994)).

[0073] The term "FcRn" refers to the neonatal Fc receptor (FcRn). FcRn is structurally similar to the major histocompatibility complex (MHC), consisting of an α-chain non-covalently bound to β2-microglobulin. The various functions of the neonatal Fc receptor FcRn are reviewed in Ghetie and Ward (2000) Annu. Rev. Immunol. 18, 739-766. FcRn plays an important role in the passive transport of immunoglobulin IgGs from the mother to the newborn and in regulating serum IgG levels. As a rescue receptor, FcRn can bind and transport endocytotic IgG in its intact form both intracellularly and intercellularly, protecting it from the default degradation pathway.

[0074] The "CH1 domain" of the constant region of the human IgG heavy chain typically extends from amino acid 118 to amino acid 215 (EU numbering system).

[0075] The "hinge region" is typically defined as extending from Glu at position 216 to Pro at position 230 of human IgG1 (Burton, Molec. Immunol. 22:161-206 (1985)). By placing the first and last cysteine ​​residues that form the inter-heavy chain disulfide bond at the same positions as IgG1, it is possible to align the hinge regions of other IgG isotypes with the IgG1 sequence.

[0076] The "CH2 domain" of the human IgG Fc region typically extends from amino acid 231 to amino acid 340. The unique feature of the CH2 domain is that it does not pair tightly with another region; instead, two N-terminal branched sugar chains are inserted between the two CH2 domains of the intact native IgG molecule. It is speculated that the sugars may act as a substitute for domain-to-domain pairing, helping to maintain the stability of the CH2 domain. (Burton, Molec. Immunol. 22:161-206 (1985)).

[0077] The “CH3” domain includes the extension from the C-terminal residue to the CH2 domain within the Fc region (from amino acid 341 to the C-terminus of the antibody sequence, typically amino acid 446 or 447 of IgG).

[0078] "Functional Fc fragments" possess the "effective functions" inherent in the natural Fc region sequence. Exemplary "effective functions" include C1q binding; complement-dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; and downregulation of cell surface receptors (such as B cell receptors; BCR). These effector functions typically require the Fc region to bind to a binding domain (such as the antibody variable region) and can be evaluated using a variety of experimental methods known in the art.

[0079] Antibodies with IgG Fc variants exhibiting "altered" FcR binding affinity or ADCC activity show enhanced or weakened FcR binding and / or ADCC activity compared to the parent peptide or peptides containing the native Fc sequence. Fc variants exhibiting "enhanced binding" to FcRs have higher binding affinity (e.g., lower apparent Kd or IC50) to at least one FcR compared to the parent peptide or peptides containing the native IgG Fc sequence. 50(Value). In some embodiments, the binding affinity is enhanced by 3 times compared to the parent peptide, for example, 5, 10, 25, 50, 60, 100, 150, 200, or even up to 500 times, or the binding affinity is increased by 25% to 1000%. Fc variants exhibit “reduced binding” to FcRs, having a lower affinity for at least one FcR compared to the parent peptide (e.g., higher apparent Kd or IC). 50 (Value). Compared with the parent peptide, its binding ability is reduced by 40% or more.

[0080] Antibody-dependent cell-mediated cytotoxicity (ADCC) is a form of cytotoxicity in which secreted Ig binds to Fc receptors (FcRs) present on certain cytotoxic cells, such as natural killer (NK) cells, neutrophils, and macrophages. This allows these cytotoxic effector cells to specifically bind to target cells carrying antigens and subsequently kill the target cells using cytotoxins. Antibodies "arm" the cytotoxic cells and are essential for this killing. Among the main cell types mediating ADCC, NK cells express only FcγRIII, while monocytes express FcγRI, FcγRII, and FcγRIII. The expression of FcRs on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991). The ADCC activity of target molecules can be assessed by in vitro ADCC experiments, described in U.S. Patent Nos. 5,500,362 or 5,821,337. Effector cells suitable for such experiments include peripheral blood mononuclear cells (PBMCs) and natural killer cells (NK cells). Alternatively, or additionally, the ADCC activity of the target molecule can also be assessed in vivo, as described, for example, in animal models disclosed in Clynes et al. PNAS (USA) 95:652-656 (1998).

[0081] Peptides containing Fc region variants exhibit "enhanced ADCC activity" or are more effective at mediating ADCC effects in the presence of human effector cells compared to peptides containing wild-type IgG Fc or parental peptides. These peptides, when experimentally present in substantially the same quantity as those containing wild-type IgG Fc (or parental peptides), mediate ADCC more effectively both in vitro and in vivo. Such variants are typically identified using any in vitro ADCC assay known in the art, such as experiments or methods for identifying ADCC activity, for example in animal models. In some embodiments, such variants mediate ADCC with a 5 to 100-fold, for example, 25 to 50-fold, efficiency improvement compared to wild-type Fc (or parental peptide).

[0082] "Complement-dependent cytotoxicity" or "CDC" refers to the lysis of target cells in the presence of complement. Activation of the classical complement pathway is initiated by the binding of the first component of the complement system (C1q) to an antibody (a subclass with a suitable structure) that binds to a homologous antigen. To assess complement activation, CDC assays can be performed, as described in Gazzano-Santoro et al., J. Immunol. Methods 202:163 (1996). Peptide variants with altered Fc region amino acid sequences and increased or decreased C1q binding capacity are described in U.S. Patent Nos. 6,194,551B1 and WO99 / 51642. The contents of these patent publications are expressly incorporated herein by reference. See also Idusogie et al. J. Immunol. 164:4178-4184 (2000).

[0083] Unless otherwise stated, a "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that are degenerate forms of each other and encode the same amino acid sequence. Nucleotide sequences encoding proteins or RNA may also include introns; for example, nucleotide sequences encoding proteins may contain introns in certain forms.

[0084] The term "operationally ligated" refers to a functional link between a regulatory sequence and a heterologous nucleotide sequence, thereby enabling the latter to be expressed. For example, the first and second nucleotide sequences are operably ligated when they are in a functional relationship. Similarly, if a promoter affects the transcription or expression of a coding sequence, the promoter and coding sequence are operably ligated. Typically, operably ligated DNA sequences are contiguous, and, if necessary, two protein-coding regions can be ligated within the same reading frame.

[0085] "Homology" refers to the sequence similarity or identity between two polypeptides or two nucleic acid molecules. If the same position in two compared sequences is the same base or amino acid monomer subunit, for example, if both DNA molecules have adenine at the same position, then the two DNA molecules are homologous at that position. The percentage of homology between two sequences is a function calculated by multiplying the number of matching or homologous positions in the two sequences to the total number of positions, and then multiplying by 100. For example, if 6 out of 10 positions in two sequences are matching or homologous, then the two sequences are 60% homologous. For instance, the DNA sequences ATTGCC and TATGGC have 50% homology. Generally, when comparing two sequences, the goal is to obtain the maximum homology.

[0086] The “effective amount” of the anti-MASP2 antibody or composition disclosed herein refers to an amount sufficient to achieve a specific purpose. The “effective amount” can be determined empirically and by known methods associated with the stated purpose.

[0087] The term "therapeutic effective amount" refers to the amount of the anti-MASP2 antibody or its composition disclosed herein that is effective in treating an individual's disease or symptoms. This includes an amount sufficient to reduce or improve the severity and / or duration of the disease or one or more of its symptoms; prevent disease progression; induce symptom resolution; prevent recurrence, development, onset, or progression of one or more disease-related symptoms; detect the disease; or enhance / improve the preventive or therapeutic effect of another therapy (e.g., a prophylactic or therapeutic agent).

[0088] As used herein, "pharmaceuticalally acceptable" or "pharmacologically compatible" means a material that has no biological activity or other undesirable properties, such as the ability to be incorporated into a pharmaceutical composition given to a patient without causing significant adverse biological reactions, or that does not interact harmfully with any other components contained in the composition. Pharmaceutically acceptable carriers or excipients preferably meet the required standards for toxicological or manufacturing testing and / or are included in the inactive ingredient guidelines prepared by the U.S. Food and Drug Administration.

[0089] The embodiments of this application described herein should be understood to include embodiments that are “composed of” and / or “substantially composed of”.

[0090] In this article, “about” is used to refer to a numerical value or parameter, including (and descriptions) variations for that value or parameter itself. For example, a description involving “about X” includes a description of “X”.

[0091] As used in this article, mentioning "not" a value or parameter usually means and describes something other than a certain value or parameter. For example, "This method cannot be used to treat type X cancer" means that this method is generally used to treat other types of cancer besides type X cancer.

[0092] Unless the context clearly indicates otherwise, the singular forms “a,” “an,” and “the” used herein and in the claims include plural objects.

[0093] Anti-MASP2 antibody

[0094] On one hand, this application provides anti-MASP2 antibodies that specifically bind to human, cynomolgus monkey, and / or mouse MASP2. These anti-MASP2 antibodies include, but are not limited to, humanized antibodies, chimeric antibodies, mouse antibodies, human antibodies, and antibody molecules comprising heavy chain and / or light chain CDRs as described herein. On the other hand, this application provides isolated antibodies that bind to MASP2. Anticipated anti-MASP2 antibodies include, for example, full-length anti-MASP2 antibodies (such as full-length IgG1 or IgG4), anti-MASP2 single-chain antibodies, anti-MASP2 Fc fusion proteins, multispecific (such as bispecific) anti-MASP2 antibodies, anti-MASP2 immunoconjugates, and the like. In some embodiments, the anti-MASP2 antibody is a full-length antibody (such as full-length IgG1 or IgG4) or its antigen-binding fragment that specifically binds to MASP2. In some embodiments, the anti-MASP2 antibody is Fab, Fab', F(ab)'2, Fab'-SH, single-chain Fv (scFv), Fv fragment, dAb, Fd, nanobody, diabody, or linear antibody. In some embodiments, an antibody that specifically binds to MASP2 means that the antibody's affinity for binding to MASP2 is at least 10 times greater than its affinity for binding to non-target antibodies (including, for example, 10, 10). 2 10 3 10 4 10 5 10 6 , or 10 7 (Multiple times). In some embodiments, non-target refers to an antigen that is not MASP2. Binding affinity can be determined by methods known in the art, such as ELISA, fluorescence-activated cell sorting (FACS) analysis, or radioimmunoprecipitation (RIA). Kd value can be determined by methods known in the art, such as surface plasmon resonance (SPR) technology or biolayer interference (BLI) technology.

[0095] While this document discusses anti-MASP2 antibodies containing human sequences (e.g., human heavy and light chain variable domains containing human CDR sequences), non-human anti-MASP2 antibodies are also considered. In some embodiments, non-human anti-MASP2 antibodies comprise the human CDR sequence and non-human frame region sequence of the anti-MASP2 antibodies described herein. In some embodiments, the non-human frame region sequence comprises any sequence used to generate heavy and / or light chain variable domains using one or more human CDR sequences as described herein, including, for example, mammals such as mice, rats, rabbits, pigs, cattle (e.g., bulls, buffalo), deer, sheep, goats, chickens, cats, dogs, ferrets, primates (e.g., apes, macaques), etc. In some embodiments, non-human anti-MASP2 antibodies comprise anti-MASP2 antibodies generated by transplanting one or more human CDR sequences as described herein into a non-human frame region (e.g., a mouse or chicken frame region sequence).

[0096] The exemplary complete amino acid sequence of human MASP2 comprises or consists of the amino acid sequence shown in SEQ ID NO: 84. The CCP1-CCP2-SP domain of human MASP2 comprises or consists of the amino acid sequence shown in SEQ ID NO: 85.

[0097] In some embodiments, the anti-MASP2 antibody described herein specifically recognizes an epitope in human MASP2. In some embodiments, the anti-MASP2 antibody cross-reacts with MASP2 in species other than humans. In other embodiments, the anti-MASP2 antibody is completely specific to human MASP2 and does not cross-react with other non-human species.

[0098] In some embodiments, the anti-MASP2 antibody cross-reacts with at least one allelic variant of the MASP2 protein (or a fragment thereof). In some embodiments, the allelic variant has up to 30 amino acid substitutions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, or 30) compared to the naturally occurring MASP2 protein (or a fragment thereof) (e.g., conserved substitutions). In some embodiments, the anti-MASP2 antibody does not cross-react with any allelic variant of the MASP2 protein (or a fragment thereof).

[0099] In some embodiments, the anti-MASP2 antibody cross-reacts with at least one interspecies variant of the MASP2 protein. In some embodiments, for example, the MASP2 protein (or a fragment thereof) is human MASP2, and the interspecies variant of the MASP2 protein (or a fragment thereof) is a variant found in cynomolgus monkeys. In some embodiments, the anti-MASP2 antibody does not cross-react with any interspecies variant of the MASP2 protein.

[0100] In some embodiments, any anti-MASP2 antibody as described herein comprises an antibody heavy chain constant region and an antibody light chain constant region. In some embodiments, the anti-MASP2 antibody comprises an IgG1 type heavy chain constant region. In some embodiments, the anti-MASP2 antibody comprises an IgG2 type heavy chain constant region. In some embodiments, the anti-MASP2 antibody comprises an IgG3 type heavy chain constant region. In some embodiments, the anti-MASP2 antibody comprises an IgG4 type heavy chain constant region. In some embodiments, the heavy chain constant region comprises (including a sequence consisting of or substantially consisting of) the amino acid sequence SEQ ID NO:80. In some embodiments, the heavy chain constant region comprises (including a sequence consisting of or substantially consisting of) the amino acid sequence SEQ ID NO:81. In some embodiments, the anti-MASP2 antibody comprises a κ light chain constant region. In some embodiments, the light chain constant region comprises (including a sequence consisting of or substantially consisting of) the amino acid sequence SEQ ID NO:82. In some embodiments, the anti-MASP2 antibody comprises a λ light chain constant region. In some embodiments, the light chain constant region comprises (including a sequence consisting of or substantially consisting of) the amino acid sequence SEQ ID NO:83. In some embodiments, the anti-MASP2 antibody includes an antibody heavy chain variable domain and an antibody light chain variable domain.

[0101] In some embodiments, the anti-MASP2 antibody includes a heavy chain variable domain (V H ), the V H Includes: a heavy chain complementarity determination region (HC-CDR)1 containing SDYAWN (SEQ ID NO:1); HC-CDR2 containing YISYSGRTSYNPSLKS (SEQ ID NO:5); and HC-CDR3 containing HYGX1X2 (SEQ ID NO:38), where X1 is D or S and X2 is H or Y; and a light chain variable structural domain (V L ), the V LIt includes: a light chain complementarity determination region (LC-CDR)1, which includes KASQNVGTNVA (SEQ ID NO: 19); LC-CDR2, which includes SASYRYS (SEQ ID NO: 26); and LC-CDR3, which includes X1QYNSX2X3X4 (SEQ ID NO: 39), wherein X1 is H or Q, X2 is N or Y, X3 is L or P, and X4 is L or T.

[0102] In some embodiments, the anti-MASP2 antibody comprises V H The V H It comprises: HC-CDR1, which comprises the amino acid sequence shown in SEQ ID NO:1; HC-CDR2, which comprises the amino acid sequence shown in SEQ ID NO:5; and HC-CDR3, which comprises the amino acid sequence shown in any of SEQ ID NOs:13-14 or a variant thereof, said variant comprising substitutions of up to about 3 amino acids (e.g., 1, 2 or 3).

[0103] In some embodiments, the anti-MASP2 antibody comprises V H The V H It includes: HC-CDR1, which contains the amino acid sequence shown in SEQ ID NO:1; HC-CDR2, which contains the amino acid sequence shown in SEQ ID NO:5; and HC-CDR3, which contains any of the amino acid sequences shown in SEQ ID NOs:13-14.

[0104] In some embodiments, the anti-MASP2 antibody comprises V L The V L It comprises: LC-CDR1, which comprises the amino acid sequence shown in SEQ ID NO:19; LC-CDR2, which comprises the amino acid sequence shown in SEQ ID NO:26; and LC-CDR3, which comprises any of the amino acid sequences shown in SEQ ID NOs:30-31 or variants thereof, the variants comprising substitutions of up to about 3 amino acids (e.g., 1, 2 or 3).

[0105] In some embodiments, the anti-MASP2 antibody comprises V L The V L It includes: LC-CDR1, which contains the amino acid sequence shown in SEQ ID NO:19; LC-CDR2, which contains the amino acid sequence shown in SEQ ID NO:26; and LC-CDR3, which contains any of the amino acid sequences shown in SEQ ID NOs:30-31.

[0106] In some embodiments, the anti-MASP2 antibody comprises V HThe V H Contains: HC-CDR1, which contains the amino acid sequence shown in SEQ ID NO:1; HC-CDR2, which contains the amino acid sequence shown in SEQ ID NO:5; and HC-CDR3, which contains the amino acid sequence shown in any of SEQ ID NOs:13-14 or a variant thereof, said variant containing substitutions of up to about 3 amino acids (e.g., 1, 2, or 3); and V L The V L It comprises: LC-CDR1, which contains the amino acid sequence shown in SEQ ID NO:19; LC-CDR2, which contains the amino acid sequence shown in SEQ ID NO:26; and LC-CDR3, which contains the amino acid sequence shown in any of SEQ ID NOs:30-31 or a variant thereof, the variant containing substitutions of up to about 3 amino acids (e.g., 1, 2 or 3).

[0107] In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains: HC-CDR1, which contains the amino acid sequence shown in SEQ ID NO:1; HC-CDR2, which contains the amino acid sequence shown in SEQ ID NO:5; and HC-CDR3, which contains any of the amino acid sequences shown in SEQ ID NOs:13-14; and V L The V L It comprises: LC-CDR1, which contains the amino acid sequence shown in SEQ ID NO:19; LC-CDR2, which contains the amino acid sequence shown in SEQ ID NO:26; and LC-CDR3, which contains any of the amino acid sequences shown in SEQ ID NOs:30-31.

[0108] In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO:1; HC-CDR2, which contains the amino acid sequence SEQ ID NO:5; HC-CDR3, which contains the amino acid sequence SEQ ID NO:13; or the V H Variants of which contain up to about 5 amino acid substitutions in their HC-CDRs; and V L The V L Contains: LC-CDR1, which contains the amino acid sequence SEQ ID NO:19; LC-CDR2, which contains the amino acid sequence SEQ ID NO:26; LC-CDR3, which contains the amino acid sequence SEQ ID NO:30; or the V LVariants of which contain up to about 5 amino acid substitutions in their LC-CDRs.

[0109] In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO:1; HC-CDR2, which contains the amino acid sequence SEQ ID NO:5; and HC-CDR3, which contains the amino acid sequence SEQ ID NO:13; and V L The V L It includes: LC-CDR1, which contains the amino acid sequence SEQ ID NO:19; LC-CDR2, which contains the amino acid sequence SEQ ID NO:26; and LC-CDR3, which contains the amino acid sequence SEQ ID NO:30.

[0110] In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO:1; HC-CDR2, which contains the amino acid sequence SEQ ID NO:5; HC-CDR3, which contains the amino acid sequence SEQ ID NO:14; or the V H Variants of which contain up to about 5 amino acid substitutions in their HC-CDRs; and V L The V L Contains: LC-CDR1, which contains the amino acid sequence SEQ ID NO:19; LC-CDR2, which contains the amino acid sequence SEQ ID NO:26; LC-CDR3, which contains the amino acid sequence SEQ ID NO:31; or the V L Variants of which contain up to about 5 amino acid substitutions in their LC-CDRs.

[0111] In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO:1; HC-CDR2, which contains the amino acid sequence SEQ ID NO:5; and HC-CDR3, which contains the amino acid sequence SEQ ID NO:14; and V L The V L It includes: LC-CDR1, which contains the amino acid sequence SEQ ID NO:19; LC-CDR2, which contains the amino acid sequence SEQ ID NO:26; and LC-CDR3, which contains the amino acid sequence SEQ ID NO:31.

[0112] In some embodiments, the anti-MASP2 antibody comprises V H The V H V containing an amino acid sequence as shown in either SEQ ID NOs:40 or 44 H Includes HC-CDR1, HC-CDR2, and HC-CDR3; and V L The V L V containing an amino acid sequence as shown in either SEQ ID NOs:62 or 65 L It includes LC-CDR1, LC-CDR2 and LC-CDR3.

[0113] In some embodiments, the anti-MASP2 antibody comprises V H It contains V as shown in the amino acid sequence SEQ ID NO:40. H Includes HC-CDR1, HC-CDR2, and HC-CDR3; and V L It contains V as shown in the amino acid sequence SEQ ID NO:62. L It includes LC-CDR1, LC-CDR2 and LC-CDR3.

[0114] In some embodiments, the anti-MASP2 antibody comprises V H It contains V as shown in the amino acid sequence SEQ ID NO:44. H Includes HC-CDR1, HC-CDR2, and HC-CDR3; and V L It contains V as shown in the amino acid sequence SEQ ID NO:65. L It includes LC-CDR1, LC-CDR2 and LC-CDR3.

[0115] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains any of the amino acid sequences shown in SEQ ID NOs:40-47 or variants thereof, wherein the variants have at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with any of the amino acid sequences shown in SEQ ID NOs:40-47; and V L The V LThe antibody comprises any of the amino acid sequences shown in SEQ ID NOs:62-68 or variants thereof, wherein the variants have at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with any of the amino acid sequences shown in SEQ ID NOs:62-68. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains any of the amino acid sequences shown in SEQ ID NOs:40-47, and V L The V L It contains any of the amino acid sequences shown in SEQ ID NOs:62-68.

[0116] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:40 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:40; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:62 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:62. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:40, and V L The V L It contains the amino acid sequence SEQ ID NO:62.

[0117] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:41 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:41; and V L The V LThe antibody comprises the amino acid sequence SEQ ID NO:63 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:63. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:41, and V L The V L It contains the amino acid sequence SEQ ID NO:63.

[0118] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:41 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:41; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:64 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:64. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:41, and V L The V L It contains the amino acid sequence SEQ ID NO:64.

[0119] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:42 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:42; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:63 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:63. In some embodiments, the anti-MASP2 antibody comprises V H The V HContains the amino acid sequence SEQ ID NO:42, and V L The V L It contains the amino acid sequence SEQ ID NO:63.

[0120] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:42 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:42; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:64 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:64. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:42, and V L The V L It contains the amino acid sequence SEQ ID NO:64.

[0121] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:43 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:43; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:63 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:63. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:43, and V L The V L It contains the amino acid sequence SEQ ID NO:63.

[0122] In some embodiments, the anti-MASP2 antibody comprises: V H The VH Contains the amino acid sequence SEQ ID NO:43 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:43; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:64 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:64. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:43, and V L The V L It contains the amino acid sequence SEQ ID NO:64.

[0123] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:44 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:44; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:65 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:65. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:44, and V L The V L It contains the amino acid sequence SEQ ID NO:65.

[0124] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:45 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:45; and V L The V LThe antibody comprises the amino acid sequence SEQ ID NO:66 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:66. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:45, and V L The V L It contains the amino acid sequence SEQ ID NO:66.

[0125] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:46 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:46; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:66 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:66. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:46, and V L The V L It contains the amino acid sequence SEQ ID NO:66.

[0126] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:47 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:47; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:66 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:66. In some embodiments, the anti-MASP2 antibody comprises V H The V HContains the amino acid sequence SEQ ID NO:47, and V L The V L It contains the amino acid sequence SEQ ID NO:66.

[0127] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:45 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:45; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:67 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:67. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:45, and V L The V L It contains the amino acid sequence SEQ ID NO:67.

[0128] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:46 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:46; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:67 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:67. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:46, and V L The V L It contains the amino acid sequence SEQ ID NO:67.

[0129] In some embodiments, the anti-MASP2 antibody comprises: V H The VH Contains the amino acid sequence SEQ ID NO:47 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:47; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:67 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:67. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:47, and V L The V L It contains the amino acid sequence SEQ ID NO:67.

[0130] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:45 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:45; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:68 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:68. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:45, and V L The V L It contains the amino acid sequence SEQ ID NO:68.

[0131] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:46 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:46; and V L The V LThe antibody comprises the amino acid sequence SEQ ID NO:68 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:68. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:46, and V L The V L It contains the amino acid sequence SEQ ID NO:68.

[0132] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:47 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:47; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:68 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:68. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:47, and V L The V L It contains the amino acid sequence SEQ ID NO:68.

[0133] In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO:2; HC-CDR2, which contains the amino acid sequence SEQ ID NO:6; HC-CDR3, which contains the amino acid sequence SEQ ID NO:15; or the V H Variants of which contain up to about 5 amino acid substitutions in their HC-CDRs; and V L The V L Contains: LC-CDR1, which contains the amino acid sequence SEQ ID NO:20; LC-CDR2, which contains the amino acid sequence SEQ ID NO:27; LC-CDR3, which contains the amino acid sequence SEQ ID NO:32; or the V LVariants of which contain up to about 5 amino acid substitutions in their LC-CDRs.

[0134] In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO:2; HC-CDR2, which contains the amino acid sequence SEQ ID NO:6; and HC-CDR3, which contains the amino acid sequence SEQ ID NO:15; and V L The V L It includes: LC-CDR1, which contains the amino acid sequence SEQ ID NO:20; LC-CDR2, which contains the amino acid sequence SEQ ID NO:27; and LC-CDR3, which contains the amino acid sequence SEQ ID NO:32.

[0135] In some embodiments, the anti-MASP2 antibody comprises V H It contains V as shown in the amino acid sequence SEQ ID NO:48. H Includes HC-CDR1, HC-CDR2, and HC-CDR3; and V L It contains V as shown in the amino acid sequence SEQ ID NO:69. L It includes LC-CDR1, LC-CDR2 and LC-CDR3.

[0136] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:48 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:48; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:69 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:69. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:48, and V L The V L It contains the amino acid sequence SEQ ID NO:69.

[0137] In some embodiments, the anti-MASP2 antibody comprises VH The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO:2; HC-CDR2, which contains the amino acid sequence SEQ ID NO:7; HC-CDR3, which contains the amino acid sequence SEQ ID NO:16; or the V H Variants of which contain up to about 5 amino acid substitutions in their HC-CDRs; and V L The V L Contains: LC-CDR1, which contains the amino acid sequence SEQ ID NO:21; LC-CDR2, which contains the amino acid sequence SEQ ID NO:27; LC-CDR3, which contains the amino acid sequence SEQ ID NO:33; or the V L Variants of which contain up to about 5 amino acid substitutions in their LC-CDRs.

[0138] In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO:2; HC-CDR2, which contains the amino acid sequence SEQ ID NO:7; and HC-CDR3, which contains the amino acid sequence SEQ ID NO:16; and V L The V L It includes: LC-CDR1, which contains the amino acid sequence SEQ ID NO:21; LC-CDR2, which contains the amino acid sequence SEQ ID NO:27; and LC-CDR3, which contains the amino acid sequence SEQ ID NO:33.

[0139] In some embodiments, the anti-MASP2 antibody comprises V H It contains V as shown in the amino acid sequence SEQ ID NO:49. H Includes HC-CDR1, HC-CDR2, and HC-CDR3; and V L It contains V as shown in the amino acid sequence SEQ ID NO:70. L It includes LC-CDR1, LC-CDR2 and LC-CDR3.

[0140] In some embodiments, the anti-MASP2 antibody comprises: V H The V HContains the amino acid sequence SEQ ID NO:49 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:49; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:70 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:70. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:49, and V L The V L It contains the amino acid sequence SEQ ID NO:70.

[0141] In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO:1; HC-CDR2, which contains the amino acid sequence SEQ ID NO:5; HC-CDR3, which contains the amino acid sequence SEQ ID NO:17; or the V H Variants of which contain up to about 5 amino acid substitutions in their HC-CDRs; and V L The V L Contains: LC-CDR1, which contains the amino acid sequence SEQ ID NO:19; LC-CDR2, which contains the amino acid sequence SEQ ID NO:26; LC-CDR3, which contains the amino acid sequence SEQ ID NO:31; or the V L Variants of which contain up to about 5 amino acid substitutions in their LC-CDRs.

[0142] In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO:1; HC-CDR2, which contains the amino acid sequence SEQ ID NO:5; and HC-CDR3, which contains the amino acid sequence SEQ ID NO:17; and V L The V LIt includes: LC-CDR1, which contains the amino acid sequence SEQ ID NO:19; LC-CDR2, which contains the amino acid sequence SEQ ID NO:26; and LC-CDR3, which contains the amino acid sequence SEQ ID NO:31.

[0143] In some embodiments, the anti-MASP2 antibody comprises V H It contains V as shown in the amino acid sequence SEQ ID NO:50. H Includes HC-CDR1, HC-CDR2, and HC-CDR3; and V L It contains V as shown in the amino acid sequence SEQ ID NO:71. L It includes LC-CDR1, LC-CDR2 and LC-CDR3.

[0144] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:50 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:50; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:71 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:71. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:50, and V L The V L It contains the amino acid sequence SEQ ID NO:71.

[0145] In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO:3; HC-CDR2, which contains the amino acid sequence SEQ ID NO:8; HC-CDR3, which contains the amino acid sequence SEQ ID NO:18; or the V H Variants of which contain up to about 5 amino acid substitutions in their HC-CDRs; and V L The V LContains: LC-CDR1, which contains the amino acid sequence SEQ ID NO:22; LC-CDR2, which contains the amino acid sequence SEQ ID NO:28; LC-CDR3, which contains the amino acid sequence SEQ ID NO:34; or the V L Variants of which contain up to about 5 amino acid substitutions in their LC-CDRs.

[0146] In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO:3; HC-CDR2, which contains the amino acid sequence SEQ ID NO:8; and HC-CDR3, which contains the amino acid sequence SEQ ID NO:18; and V L The V L It includes: LC-CDR1, which contains the amino acid sequence SEQ ID NO:22; LC-CDR2, which contains the amino acid sequence SEQ ID NO:28; and LC-CDR3, which contains the amino acid sequence SEQ ID NO:34.

[0147] In some embodiments, the anti-MASP2 antibody comprises V H It contains V as shown in the amino acid sequence SEQ ID NO:51. H Includes HC-CDR1, HC-CDR2, and HC-CDR3; and V L It contains V as shown in the amino acid sequence SEQ ID NO:72. L It includes LC-CDR1, LC-CDR2 and LC-CDR3.

[0148] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:51 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:51; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:72 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:72. In some embodiments, the anti-MASP2 antibody comprises V H The V HContains the amino acid sequence SEQ ID NO:51, and V L The V L It contains the amino acid sequence SEQ ID NO:72.

[0149] In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO:3; HC-CDR2, which contains the amino acid sequence SEQ ID NO:9; HC-CDR3, which contains the amino acid sequence SEQ ID NO:18; or the V H Variants of which contain up to about 5 amino acid substitutions in their HC-CDRs; and V L The V L Contains: LC-CDR1, which contains the amino acid sequence SEQ ID NO:23; LC-CDR2, which contains the amino acid sequence SEQ ID NO:29; LC-CDR3, which contains the amino acid sequence SEQ ID NO:35; or the V L Variants of which contain up to about 5 amino acid substitutions in their LC-CDRs.

[0150] In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO:3; HC-CDR2, which contains the amino acid sequence SEQ ID NO:9; and HC-CDR3, which contains the amino acid sequence SEQ ID NO:18; and V L The V L It includes: LC-CDR1, which contains the amino acid sequence SEQ ID NO:23; LC-CDR2, which contains the amino acid sequence SEQ ID NO:29; and LC-CDR3, which contains the amino acid sequence SEQ ID NO:35.

[0151] In some embodiments, the anti-MASP2 antibody comprises V H It contains V as shown in the amino acid sequence SEQ ID NO:52. H Includes HC-CDR1, HC-CDR2, and HC-CDR3; and V L It contains V as shown in the amino acid sequence SEQ ID NO:73. L It includes LC-CDR1, LC-CDR2 and LC-CDR3.

[0152] In some embodiments, the anti-MASP2 antibody comprises: VH The V H Contains the amino acid sequence SEQ ID NO:52 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:52; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:73 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:73. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:52, and V L The V L It contains the amino acid sequence SEQ ID NO:73.

[0153] In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO:3; HC-CDR2, which contains the amino acid sequence SEQ ID NO:10; HC-CDR3, which contains the amino acid sequence SEQ ID NO:18; or the V H Variants of which contain up to about 5 amino acid substitutions in their HC-CDRs; and V L The V L Contains: LC-CDR1, which contains the amino acid sequence SEQ ID NO:22; LC-CDR2, which contains the amino acid sequence SEQ ID NO:28; LC-CDR3, which contains the amino acid sequence SEQ ID NO:34; or the V L Variants of which contain up to about 5 amino acid substitutions in their LC-CDRs.

[0154] In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO:3; HC-CDR2, which contains the amino acid sequence SEQ ID NO:10; and HC-CDR3, which contains the amino acid sequence SEQ ID NO:18; and V L The V LIt includes: LC-CDR1, which contains the amino acid sequence SEQ ID NO:22; LC-CDR2, which contains the amino acid sequence SEQ ID NO:28; and LC-CDR3, which contains the amino acid sequence SEQ ID NO:34.

[0155] In some embodiments, the anti-MASP2 antibody comprises V H It contains V as shown in the amino acid sequence SEQ ID NO:53. H Includes HC-CDR1, HC-CDR2, and HC-CDR3; and V L It contains V as shown in the amino acid sequence SEQ ID NO:72. L It includes LC-CDR1, LC-CDR2 and LC-CDR3.

[0156] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:53 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:53; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:72 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:72. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:53, and V L The V L It contains the amino acid sequence SEQ ID NO:72.

[0157] In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO:4; HC-CDR2, which contains the amino acid sequence SEQ ID NO:11; HC-CDR3, which contains the amino acid sequence SEQ ID NO:18; or the V H Variants of which contain up to about 5 amino acid substitutions in their HC-CDRs; and V L The V LContains: LC-CDR1, which contains the amino acid sequence SEQ ID NO:24; LC-CDR2, which contains the amino acid sequence SEQ ID NO:28; LC-CDR3, which contains the amino acid sequence SEQ ID NO:34; or the V L Variants of which contain up to about 5 amino acid substitutions in their LC-CDRs.

[0158] In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO:4; HC-CDR2, which contains the amino acid sequence SEQ ID NO:11; and HC-CDR3, which contains the amino acid sequence SEQ ID NO:18; and V L The V L It includes: LC-CDR1, which contains the amino acid sequence SEQ ID NO:24; LC-CDR2, which contains the amino acid sequence SEQ ID NO:28; and LC-CDR3, which contains the amino acid sequence SEQ ID NO:34.

[0159] In some embodiments, the anti-MASP2 antibody comprises V H It contains V as shown in the amino acid sequence SEQ ID NO:54. H Includes HC-CDR1, HC-CDR2, and HC-CDR3; and V L It contains V as shown in the amino acid sequence SEQ ID NO:74. L It includes LC-CDR1, LC-CDR2 and LC-CDR3.

[0160] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:54 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:54; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:74 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:74. In some embodiments, the anti-MASP2 antibody comprises V H The V HContains the amino acid sequence SEQ ID NO:54, and V L The V L It contains the amino acid sequence SEQ ID NO:74.

[0161] In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO:3; HC-CDR2, which contains the amino acid sequence SEQ ID NO:12; HC-CDR3, which contains the amino acid sequence SEQ ID NO:18; or the V H Variants of which contain up to about 5 amino acid substitutions in their HC-CDRs; and V L The V L Contains: LC-CDR1, which contains the amino acid sequence SEQ ID NO:23; LC-CDR2, which contains the amino acid sequence SEQ ID NO:28; LC-CDR3, which contains the amino acid sequence SEQ ID NO:36; or the V L Variants of which contain up to about 5 amino acid substitutions in their LC-CDRs.

[0162] In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO:3; HC-CDR2, which contains the amino acid sequence SEQ ID NO:12; and HC-CDR3, which contains the amino acid sequence SEQ ID NO:18; and V L The V L It includes: LC-CDR1, which contains the amino acid sequence SEQ ID NO:23; LC-CDR2, which contains the amino acid sequence SEQ ID NO:28; and LC-CDR3, which contains the amino acid sequence SEQ ID NO:36.

[0163] In some embodiments, the anti-MASP2 antibody comprises V H It contains V as shown in the amino acid sequence SEQ ID NO:55. H Includes HC-CDR1, HC-CDR2, and HC-CDR3; and V L It contains V as shown in the amino acid sequence SEQ ID NO:75. L It includes LC-CDR1, LC-CDR2 and LC-CDR3.

[0164] In some embodiments, the anti-MASP2 antibody comprises: VH The V H Contains the amino acid sequence SEQ ID NO:55 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:55; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:75 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:75. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:55, and V L The V L It contains the amino acid sequence SEQ ID NO:75.

[0165] In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO:3; HC-CDR2, which contains the amino acid sequence SEQ ID NO:10; HC-CDR3, which contains the amino acid sequence SEQ ID NO:18; or the V H Variants of which contain up to about 5 amino acid substitutions in their HC-CDRs; and V L The V L Contains: LC-CDR1, which contains the amino acid sequence SEQ ID NO:25; LC-CDR2, which contains the amino acid sequence SEQ ID NO:28; LC-CDR3, which contains the amino acid sequence SEQ ID NO:37; or the V L Variants of which contain up to about 5 amino acid substitutions in their LC-CDRs.

[0166] In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains: HC-CDR1, which contains the amino acid sequence SEQ ID NO:3; HC-CDR2, which contains the amino acid sequence SEQ ID NO:10; and HC-CDR3, which contains the amino acid sequence SEQ ID NO:18; and V L The V LIt includes: LC-CDR1, which contains the amino acid sequence SEQ ID NO:25; LC-CDR2, which contains the amino acid sequence SEQ ID NO:28; and LC-CDR3, which contains the amino acid sequence SEQ ID NO:37.

[0167] In some embodiments, the anti-MASP2 antibody comprises V H It contains V as shown in the amino acid sequence SEQ ID NO:56. H Includes HC-CDR1, HC-CDR2, and HC-CDR3; and V L It contains V as shown in the amino acid sequence SEQ ID NO:76. L It includes LC-CDR1, LC-CDR2 and LC-CDR3.

[0168] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains any of the amino acid sequences shown in SEQ ID NOs:56-61 or variants thereof, said variants having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with any of the amino acid sequences shown in SEQ ID NOs:56-61; and V L The V L The antibody comprises any of the amino acid sequences shown in SEQ ID NOs:76-79 or variants thereof, wherein the variants have at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with any of the amino acid sequences shown in SEQ ID NOs:76-79. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains any of the amino acid sequences shown in SEQ ID NOs:56-61, and V L The V L It contains any of the amino acid sequences shown in SEQ ID NOs:76-79.

[0169] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:56 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:56; and V L The V LThe antibody comprises the amino acid sequence SEQ ID NO:76 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:76. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:56, and V L The V L It contains the amino acid sequence SEQ ID NO:76.

[0170] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:57 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:57; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:77 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:77. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:57, and V L The V L It contains the amino acid sequence SEQ ID NO:77.

[0171] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:58 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:58; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:77 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:77. In some embodiments, the anti-MASP2 antibody comprises V H The V HContains the amino acid sequence SEQ ID NO:58, and V L The V L It contains the amino acid sequence SEQ ID NO:77.

[0172] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:59 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:59; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:77 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:77. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:59, and V L The V L It contains the amino acid sequence SEQ ID NO:77.

[0173] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:60 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:60; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:77 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:77. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:60, and V L The V L It contains the amino acid sequence SEQ ID NO:77.

[0174] In some embodiments, the anti-MASP2 antibody comprises: V H The VH Contains the amino acid sequence SEQ ID NO:61 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:61; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:77 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:77. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:61, and V L The V L It contains the amino acid sequence SEQ ID NO:77.

[0175] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:57 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:57; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:78 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:78. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:57, and V L The V L It contains the amino acid sequence SEQ ID NO:78.

[0176] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:58 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:58; and V L The V LThe antibody comprises the amino acid sequence SEQ ID NO:78 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:78. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:58, and V L The V L It contains the amino acid sequence SEQ ID NO:78.

[0177] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:59 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:59; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:78 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:78. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:59, and V L The V L It contains the amino acid sequence SEQ ID NO:78.

[0178] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:60 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:60; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:78 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:78. In some embodiments, the anti-MASP2 antibody comprises V H The V HContains the amino acid sequence SEQ ID NO:60, and V L The V L It contains the amino acid sequence SEQ ID NO:78.

[0179] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:61 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:61; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:78 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:78. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:61, and V L The V L It contains the amino acid sequence SEQ ID NO:78.

[0180] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:57 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:57; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:79 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:79. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:57, and V L The V L It contains the amino acid sequence SEQ ID NO:79.

[0181] In some embodiments, the anti-MASP2 antibody comprises: V H The VH Contains the amino acid sequence SEQ ID NO:58 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:58; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:79 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:79. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:58, and V L The V L It contains the amino acid sequence SEQ ID NO:79.

[0182] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:59 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:59; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:79 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:79. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:59, and V L The V L It contains the amino acid sequence SEQ ID NO:79.

[0183] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:60 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:60; and V L The V LThe antibody comprises the amino acid sequence SEQ ID NO:79 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:79. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:60, and V L The V L It contains the amino acid sequence SEQ ID NO:79.

[0184] In some embodiments, the anti-MASP2 antibody comprises: V H The V H Contains the amino acid sequence SEQ ID NO:61 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:61; and V L The V L The antibody comprises the amino acid sequence SEQ ID NO:79 or a variant thereof, said variant having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with the amino acid sequence SEQ ID NO:79. In some embodiments, the anti-MASP2 antibody comprises V H The V H Contains the amino acid sequence SEQ ID NO:61, and V L The V L It contains the amino acid sequence SEQ ID NO:79.

[0185] In some embodiments, the amino acid substitutions described above are limited to the “Exemplary Substitutions” shown in Table 4 herein. In some embodiments, the amino acid substitutions are limited to the “Preferred Substitutions” shown in Table 4 herein.

[0186] In some embodiments, the functional epitope can be resolved using a combined alanine scanning technique. In this process, the combined alanine scanning technique can be used to identify the amino acids in the MASP2 protein essential for interaction with anti-MASP2 antibodies. In some embodiments, the epitope is conformational, and the epitope can also be identified using the crystal structure of an anti-MASP2 antibody that binds to the MASP2 protein.

[0187] In some embodiments, this application provides an antibody that competitively binds to MASP2, in conjunction with any of the anti-MASP2 antibodies described herein. In some embodiments, an antibody is provided that is capable of competitively binding to an epitope on MASP2, in conjunction with any of the anti-MASP2 antibodies described herein. In some embodiments, an anti-MASP2 antibody is provided that contains V H and V L The anti-MASP2 antibody molecule binds to the same epitope, wherein the V H Contains any of the amino acid sequences shown in SEQ ID NOs:40-61, and the V L Contains any of the amino acid sequences shown in SEQ ID NOs:62-79. In some embodiments, an anti-MASP2 antibody is provided, which, together with V H and V L The anti-MASP2 antibody competitively binds to MASP2, wherein the V H Contains any of the amino acid sequences shown in SEQ ID NOs:40-61, and the V L It contains any of the amino acid sequences shown in SEQ ID NOs:62-79.

[0188] In some embodiments, a competition assay can be used to identify monoclonal antibodies that competitively bind to MASP2 with the anti-MASP2 antibody described herein. A competition assay can determine whether two antibodies bind to the same epitope by identifying identical or spatially overlapping epitopes or by one antibody competitively inhibiting the binding of another antibody to the antigen. In some embodiments, such a competing antibody binds to the same epitope as the antibody described herein. Some exemplary competition assays include, but are not limited to, conventional assays as described in Harlow and Lane (1988) Antibodies: A Laboratory Manual ch.14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY). Detailed exemplary methods for resolving antibody-bound epitopes are described in Morris (1996) "Epitope Mapping Protocols," in Methods in Molecular Biology vol.66 (Humana Press, Totowa, NJ). In some embodiments, if each antibody blocks 50% or more of the binding of another antibody, they are said to bind to the same epitope. In some embodiments, the antibody competing with the anti-MASP2 antibody described herein is a chimeric antibody, a humanized antibody, or a fully human antibody.

[0189] Exemplary anti-MASP2 antibody sequences are shown in Tables 2 and 3, where CDRs are numbered according to the Kabat definition. Those skilled in the art will recognize that various known algorithms exist for predicting CDR locations and defining the variable regions of the antibody light and heavy chains, including CDRs and V of antibodies as described herein. H and / or V L Sequences, but antibodies based on prediction algorithms rather than those exemplified in the table below are also within the scope of this application.

[0190] Table 2. Exemplary anti-MASP2 antibody CDR sequences

[0191]

[0192]

[0193]

[0194]

[0195] Table 3. Exemplary Sequences

[0196]

[0197]

[0198]

[0199]

[0200] lectins

[0201] Collagen lectins (mannose-binding lectin (MBL), collagen lectin-10 (CL-10), collagen lectin-11 (CL-11)) and fibrinogens (ficolin-1, ficolin-2, ficolin-3)) are collectively referred to as lectins.

[0202] Mannose-binding lectin (MBL), also known as mannan-binding lectin and mannose / mannan-binding protein (MBP), is a polymer of a basic triplet subunit composed of identical polypeptide chains. Its molecule has four regions: an N-terminal cysteine-rich domain, a collagen-like domain, an α-helix neck region, and a C-terminal carbohydrate recognition domain (Thiel, Steffen, and Mihaela Gadjeva. Advances in experimental medicine and biology vol. 653(2009):58-73).

[0203] MBL and Ca 2+ Cation binding allows it to recognize carbohydrate residues such as D-mannose (D-Man), N-acetyl-D-glucosamine (D-GlcNAc), or L-fucose (L-Fuc). This enables it to interact with many microbial polysaccharides or glycoconjugates, such as membrane polysaccharides, lipopolysaccharides, and fungal mannans. Furthermore, it can bind to phospholipids and nucleic acids. It is important to emphasize that MBL can recognize not only a variety of pathogens but also senescent fibroblasts (Tomaiuolo, Rossella et al. Aging cell vol. 11, 3(2012): 394-400), late-stage apoptotic and necrotic cells (Nauta, Alma J et al. "European journal of immunology vol. 33, 10(2003): 2853-63") and some cancer cells carrying abnormal glycosylated surface structures (Fujita, T et al. Japanese journal of cancer research: Gann vol. 86, 2(1995): 187-92).

[0204] Collagen lectin-10 (CL-10, also known as human liver collagen lectin-1, CL-L1) and collagen lectin-11 (CL-11 or human kidney collagen lectin-1, CL-K1) are two other collagen lectins that can activate complement via the lectin pathway. They can form heterooligomers, which are referred to as CL-LK (Henriksen, Maiken L et al. Journal of immunological methods vol.413(2014):25-31). Hansen et al. reported that CL-10 and CL-11 are widely distributed in tissues and highly expressed in endocrine / exocrine tissues and mucosa (Hansen, Soren WK et al. Frontiersin immunology vol.9 1757.31 Jul.2018). In the presence of calcium ions, collagen lectin-11 can recognize carbohydrate ligands such as D-mannose (D-Man), L-fucose (L-Fuc), and N-acetyl-D-glucosamine (D-GlcNAc). In addition to its ability to interact with the surface structures of some Gram-negative and Gram-positive bacteria, fungi, and influenza A viruses (Hansen, Soren W Ke et al. Immunobiology vol.221,10(2016):1058-67. Ma, Ying Jie et al. Journal of Innate Immunity vol.5,3(2013):242-50), it has also been found to bind to DNA from various sources, and it is speculated that it may contribute to responses with apoptotic cells, neutrophil extracellular traps, and biomembranes (Henriksen, Maiken L et al. Molecular Immunology vol.56,4(2013):757-67). In addition, CL-11 is believed to participate in complement-mediated ischemic injury by interacting with L-fucose at sites of ischemic stress (Farrar, Conrad A et al. The Journal of clinical investigation vol.126,5(2016):1911-25; Nauser, Christopher L et al. Frontiers in immunology vol.92023.6Sep.2018).

[0205] CL-10 can recognize D-mannose (D-Man), N-acetyl-D-glucosamine (D-GlcNAc), D-galactose (D-Gal), D-fucose (D-Fuc), and L-fucose (L-Fuc). Although the microbial / abnormal self-structure targeted by this collagen agglutinin protein has not been determined, as a component of CL-LK heterooligomers, it may broaden the scope of their interactions and / or alter their affinities (Hansen, Soren WK et al. "Frontiers in immunology vol.91757.31 Jul.2018).

[0206] Fibrinogens, like collagen lectins, are oligomeric, collagen-associated pattern recognition molecules. While their structure and activity are generally similar to collagen lectins, they lack the typical lectin (carbohydrate-binding) domain and instead possess a C-terminal fibrinogen-like region responsible for interacting with target structures. Fibrinogens bind to acetyl groups (not hydroxyl groups, as is typical of lectins) but are not necessarily present in sugar residues (Thiel, Steffen. Molecular immunology vol.44,16(2007):3875-88; Matsushita, Misao et al. Archivum immunologiae et therapiae experimentalis vol.61,4(2013):273-83).

[0207] Ficolin-1, also known as M-ficolin, recognizes ligands such as N-acetyl-D-glucosamine (D-GlcNAc), N-acetyl-D-mannosamine (D-ManNAc), N-acetyl-D-galactosamine (D-GalNAc), and sialic acid. In addition to binding to microbial surface structures (such as bacterial envelope polysaccharides), it also binds to mitochondria of damaged host cells and apoptotic / necrotic cells (through a complex with permein-3), which is important for maintaining homeostasis. It is worth emphasizing that sialic acid-rich glycoproteins are frequently overexpressed on the surface of metastatic cancer cells (Brinkmann, Christel R et al. The Journal of Biological Chemistry vol.288,12(2013):8016-8027; Ma, Ying Jie et al. Journal of Immunology (Baltimore, Md.:1950) vol.191,3(2013):1324-33).

[0208] Compared to other fibrinogens, fibrinogen-2 (or L-fibrinogen) has four binding sites in its fibrinogen (FBG) domain, enabling it to recognize a wide range of ligands (N-acetyl-D-glucosamine (D-GlcNAc), N-acetyl-D-galactosamine (D-GalNAc), N-acetyl-D-mannosamine (D-ManNAc), D-galactose (D-Gal) and non-carbohydrate compounds such as N-acetylated cysteine ​​or acetylcholine) (Garlatti, Virginie et al. The EMBO journal vol. 26, 2(2007): 623-33). Fibrinogen-2 targets microbial structures including bacterial capsular polysaccharides, lipoteichoic acid, and 1,3-β-glucan derived from fungi. Furthermore, it can also recognize elastin and DNA. Similar to fibrin-1, fibrin-2 may help clear late-stage apoptotic cells (Kuraya, Mikio et al. Immunobiology vol.209,9(2005):689-97; Jensen, Maria Lund et al. Molecularimmunology vol.44,5(2007):856-65), thereby maintaining tissue homeostasis.

[0209] Ficolin-3 (also known as H-fibrin or Hakata antigen), like other fibrinogens, recognizes acetylated sugars, as well as D-fucose, L-fucose, and D-galactose (Garlatti, Virginie et al. The EMBO journal vol. 26, 2(2007): 623-33). Although it has the highest serum concentration among pattern recognition molecules associated with the lectin pathway (median close to 20 μg / mL in adults), no microbial ligands have yet been identified. However, it has been shown to contribute to the clearance of apoptotic cells and to interact with ovarian cancer cells. Recently, studies have shown that fibrin-3 and fibrin-2 may form heterogeneous complexes in the blood: they may have additional biological relevance compared to their parent molecules (Jarlhelt, Ida et al. Journal of immunology (Baltimore, Md.: 1950) vol. 204, 7(2020): 1919-1928).

[0210] MASPs

[0211] Initially, it was discovered that MASP family proteins could form complexes with mannose-binding lectins (MBL), hence the name MBL-associated serine proteases. However, it was later found that they could also interact with fibrinogens, as well as collagen lectins-10 and-11. In addition to proteolytic enzymes (MASP-1, MASP-2, MASP-3), this family also includes inactive factors (MAp19, MAp44) (Cedzynski, Maciej et al. Journal of biomedicine & biotechnology vol. 2012(2012):363246; Matsushita, Misao et al. Archivum immunologie et therapiae experimentalis vol. 61,4(2013):273-83).

[0212] Generally, MASP proenzymes are single-chain polypeptide proteins (such as the specific C1r and C1s proteins of the classical pathway), composed of six domains: CUB1 (C1r / C1, sea urchin epidermis, bone morphogenetic protein), EGF (epidermal growth factor), CUB2, CCP1 (complement control protein), CCP-2, and SP (serine protease, catalytic activity). Upon activation, the peptide bond between the CCP2 and SP domains is cleaved, resulting in heavy and light chains linked by disulfide bonds. The CUB1-EGF-CUB2 fragment can dimerize MASP molecules and form complexes with collagen lectins or fibrinogens (Kjaer, Troels R et al. Structure (London, England: 1993) vol. 23, 2(2015): 342-51).

[0213] MASP-1, MASP-3, and the non-enzymatically active MASP44 (MBL-associated protein, 44kDA, also known as MAP-1) are products of the MASP1 / 3 genes. MASP-1 can cleave C2, and the cleavage product binds to C4b (with lower efficiency), thus initially thought to upregulate the activation of the lectin pathway. However, it has now been shown to play a key role in MASP-2 activation. Furthermore, it may contribute to the activation of the coagulation cascade: fibrinogen, factor XIII, and thrombin-activated fibrinolysis inhibitors (TAFIs) are its substrates. In addition, its thrombin-like activity can cleave protease-activated receptor-4, a mediator of inflammation and platelet activation. Dobo et al. demonstrated that high molecular weight kininogen is another substrate of MASP-1 (Dobó, József et al. PloS onevol. 6, 5 (2011): e20036). This activity (similar to kinin) can activate the release of bradykinin, a highly pro-inflammatory mediator of the contact system. Furthermore, studies have found that MASP-1 contributes to the pro-inflammatory activation of endothelial cells and increases their permeability (Jani, Péter K et al. PloS one vol.9, 1e87104.29 Jan.2014; Debreczeni, Márta L et al. Frontiers in immunology vol.10 991.3 May.2019). More recently, it has been reported that MASP-1 affects the transcription of the alternative pathway factor D (Holers, V Michael et al. Frontiers in immunology vol.11 201.21 Feb.2020).

[0214] The first described physiological substrate of MASP-3 was insulin-like growth factor binding protein-5 (IGFPB-5). IGFPB-5 is a regulator of the activity of IGFs (factors that affect cell proliferation, differentiation, motility, and survival). Because it competes with MASP-2 for binding pattern recognition lectins, MASP-3 was thought to downregulate lectin pathway activation. However, later reports indicated that the natural substrate of MASP-3 is a precursor to factor D, thus it is directly involved in the activation of alternative pathways (Pihl, Rasmus et al. Journal of Immunology (Baltimore, Md.: 1950), ji1700518.9 Aug. 2017; Hayashi, Manabu et al. Journal of Immunology (Baltimore, Md.: 1950) vol. 203, 6(2019): 1411-1416).

[0215] MAp44 (or MAP-1) shares four common domains (CUB1, EGF, CUB2, CCP1) with MASP-1 and MASP-3. The specific exons of this protein encode an additional 17 amino acid residues at the C-terminus. Its biological role is uncertain, but it is thought to downregulate lectin pathway activity by competing with MASPs for binding to MBL. It has also been shown to contribute to the regulation of heart development (Mortensen, Simon A et al. "Journal of Immunology (Baltimore, Md.: 1950) vol. 198, 8(2017): 3118-3126").

[0216] Both MASP-2 and the non-enzymatically active MASP19 (MBL-associated protein, 19 kDa or sMAP, small MBL-associated protein) are encoded by the MASP2 gene. MASP-2 can efficiently cleave C4 and C2, thus it is a key enzyme for lectin pathway activation. Furthermore, it can activate prothrombin and participate in the activation of the coagulation system (Garred, Peter et al. Immunological reviews vol. 274, 1(2016): 74-97). Although another substrate of MASP-2 is kininogen, its cleavage does not lead to bradykinin production (Dobó, József et al. PloS one vol. 6, 5(2011): e20036).

[0217] Like MASP-1, MASP-2 has recently been reported to be involved in the transcriptional regulation of factor D. MAp19 consists of two MASP-2 first domains and an additional four amino acid residues at the C-terminus (encoded by map19-specific exons) (Garred, Peter et al. Immunological reviews vol.274,1(2016):74-97).

[0218] Full-length anti-MASP2 antibody

[0219] In some embodiments, the anti-MASP2 antibody is a full-length anti-MASP2 antibody. In some embodiments, the full-length anti-MASP2 antibody is IgA, IgD, IgE, IgG, or IgM. In some embodiments, the full-length anti-MASP2 antibody includes a constant IgG region, such as a constant region of IgG1, IgG2, IgG3, IgG4, or a variant thereof. In some embodiments, the full-length anti-MASP2 antibody includes a λ light chain constant region. In some embodiments, the full-length anti-MASP2 antibody includes a κ light chain constant region. In some embodiments, the full-length anti-MASP2 antibody is a full-length human anti-MASP2 antibody. In some embodiments, the full-length anti-MASP2 antibody includes a mouse immunoglobulin Fc sequence. In some embodiments, the full-length anti-MASP2 antibody includes an altered or otherwise modified Fc sequence such that it has enhanced effector functions of antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

[0220] Therefore, for example, in some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, the anti-MASP2 antibody specifically binding to MASP2. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0221] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG2 constant region is provided, the anti-MASP2 antibody specifically binding to MASP2. In some embodiments, the IgG2 is human IgG2. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0222] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG3 constant region is provided, the anti-MASP2 antibody specifically binding to MASP2. In some embodiments, the IgG3 is human IgG3. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0223] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, the anti-MASP2 antibody specifically binding to MASP2. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0224] In some embodiments, a full-length anti-MASP2 antibody comprising a constant region of IgG1 is provided, wherein the anti-MASP2 antibody comprises: a) a heavy chain variable domain comprising: HC-CDR1, comprising any of the amino acid sequences shown in SEQ ID NOs:1-4 or variants thereof, the variants comprising substitutions of up to about 3 (e.g., 1, 2, or 3) amino acids; HC-CDR2, comprising any of the amino acid sequences shown in SEQ ID NOs:5-12 or variants thereof, the variants comprising substitutions of up to about 3 (e.g., 1, 2, or 3) amino acids; and HC-CDR3, comprising any of the amino acid sequences shown in SEQ ID NOs:13-18 or variants thereof, the variants comprising substitutions of up to about 3 (e.g., 1, 2, or 3) amino acids; and b) a light chain variable domain comprising: LC-CDR1, comprising SEQ ID NOs:1-1-2, the heavy chain variable domain comprising: HC-CDR1, comprising any of the amino acid sequences shown in ... The amino acid sequences or variants thereof shown in SEQ ID NOs:19-25, wherein the variants contain substitutions of up to about 3 amino acids (e.g., 1, 2, or 3), LC-CDR2, which contains amino acid sequences or variants thereof shown in SEQ ID NOs:26-29, wherein the variants contain substitutions of up to about 3 amino acids (e.g., 1, 2, or 3); and LC-CDR3, which contains amino acid sequences or variants thereof shown in SEQ ID NOs:30-37, wherein the variants contain substitutions of up to about 3 amino acids (e.g., 1, 2, or 3). In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0225] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG2 constant region is provided, wherein the anti-MASP2 antibody comprises: a) a heavy chain variable domain comprising: HC-CDR1, comprising any of the amino acid sequences shown in SEQ ID NOs: 1-4 or variants thereof, the variants comprising substitutions of up to about 3 (e.g., 1, 2, or 3) amino acids; HC-CDR2, comprising any of the amino acid sequences shown in SEQ ID NOs: 5-12 or variants thereof, the variants comprising substitutions of up to about 3 (e.g., 1, 2, or 3) amino acids; and HC-CDR3, comprising any of the amino acid sequences shown in SEQ ID NOs: 13-18 or variants thereof, the variants comprising substitutions of up to about 3 (e.g., 1, 2, or 3) amino acids; and b) a light chain variable domain comprising: LC-CDR1, comprising SEQ ID NOs: 1-4 or variants thereof, the heavy chain variable domain comprising: HC-CDR1, comprising any of the amino acid sequences shown in SEQ ID NOs: 1-4 or variants thereof, the variants comprising substitutions of up to about 3 (e.g., 1, 2, or 3) amino acids; and b) a light chain variable domain comprising: LC-CDR1, comprising any of the amino acid sequences shown in SEQ ID NOs: 1-4 or variants thereof, the heavy chain variable domain comprising: HC-CDR2 ... The amino acid sequences or variants thereof shown in SEQ ID NOs:19-25, wherein the variants contain substitutions of up to about 3 amino acids (e.g., 1, 2, or 3); LC-CDR2, which contains amino acid sequences or variants thereof shown in SEQ ID NOs:26-29, wherein the variants contain substitutions of up to about 3 amino acids (e.g., 1, 2, or 3); and LC-CDR3, which contains amino acid sequences or variants thereof shown in SEQ ID NOs:30-37, wherein the variants contain substitutions of up to about 3 amino acids (e.g., 1, 2, or 3). In some embodiments, the IgG2 is human IgG2. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0226] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG3 constant region is provided, wherein the anti-MASP2 antibody comprises: a) a heavy chain variable domain comprising: HC-CDR1 comprising any of the amino acid sequences shown in SEQ ID NOs:1-4 or variants thereof, the variants comprising substitutions of up to about 3 (e.g., 1, 2, or 3) amino acids; HC-CDR2 comprising any of the amino acid sequences shown in SEQ ID NOs:5-12 or variants thereof, the variants comprising substitutions of up to about 3 (e.g., 1, 2, or 3) amino acids; and HC-CDR3 comprising any of the amino acid sequences shown in SEQ ID NOs:13-18 or variants thereof, the variants comprising substitutions of up to about 3 (e.g., 1, 2, or 3) amino acids; and b) a light chain variable domain comprising: LC-CDR1 comprising SEQ ID NOs:1-1-2 or variants thereof, the heavy chain variable domain comprising: HC-CDR1 comprising any of the amino acid sequences shown in SEQ ID NOs:1-1-2 or variants thereof, the heavy chain variable domain comprising: HC-CDR1 comprising any of the amino acid sequences shown in SEQ ID NOs:1-1-2 or variants thereof, the heavy chain variable domain comprising: HC-CDR2 ... The amino acid sequences shown in SEQ ID NOs:19-25 or variants thereof, wherein the variants contain substitutions of up to about 3 amino acids (e.g., 1, 2, or 3); LC-CDR2, which contains amino acid sequences shown in SEQ ID NOs:26-29 or variants thereof, wherein the variants contain substitutions of up to about 3 amino acids (e.g., 1, 2, or 3); and LC-CDR3, which contains amino acid sequences shown in SEQ ID NOs:30-37 or variants thereof, wherein the variants contain substitutions of up to about 3 amino acids (e.g., 1, 2, or 3). In some embodiments, the IgG3 is human IgG3. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0227] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: a) a heavy chain variable domain comprising: HC-CDR1, comprising any of the amino acid sequences shown in SEQ ID NOs: 1-4 or variants thereof, the variants comprising substitutions of up to about 3 (e.g., 1, 2, or 3) amino acids; HC-CDR2, comprising any of the amino acid sequences shown in SEQ ID NOs: 5-12 or variants thereof, the variants comprising substitutions of up to about 3 (e.g., 1, 2, or 3) amino acids; and HC-CDR3, comprising any of the amino acid sequences shown in SEQ ID NOs: 13-18 or variants thereof, the variants comprising substitutions of up to about 3 (e.g., 1, 2, or 3) amino acids; and b) a light chain variable domain comprising: LC-CDR1, comprising SEQ ID NOs: 1-4 or variants thereof, the heavy chain variable domain comprising: HC-CDR1, comprising any of the amino acid sequences shown in SEQ ID NOs: 1-4 or variants thereof, the heavy chain variable domain comprising: HC-CDR2 ... The amino acid sequences shown in SEQ ID NOs:19-25 or variants thereof, wherein the variants contain substitutions of up to about 3 amino acids (e.g., 1, 2, or 3), LC-CDR2, which contains amino acid sequences shown in SEQ ID NOs:26-29 or variants thereof, wherein the variants contain substitutions of up to about 3 amino acids (e.g., 1, 2, or 3), and LC-CDR3, which contains amino acid sequences shown in SEQ ID NOs:30-37 or variants thereof, wherein the variants contain substitutions of up to about 3 amino acids (e.g., 1, 2, or 3). In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0228] In some embodiments, a full-length anti-MASP2 antibody comprising a constant region of IgG1 is provided, wherein the anti-MASP2 antibody comprises: a) a heavy chain variable domain comprising: HC-CDR1 comprising any of the amino acid sequences shown in SEQ ID NOs: 1-4, HC-CDR2 comprising any of the amino acid sequences shown in SEQ ID NOs: 5-12, and HC-CDR3 comprising any of the amino acid sequences shown in SEQ ID NOs: 13-18, or a variant of the heavy chain variable domain having its HC-CDR sequence comprising substitutions of up to about 5 (e.g., 1, 2, 3, 4, or 5) amino acids; and b) a light chain variable domain comprising: LC-CDR1 comprising any of the amino acid sequences shown in SEQ ID NOs: 19-25, LC-CDR2 comprising any of the amino acid sequences shown in SEQ ID NOs: 26-29, and LC-CDR3 comprising any of the amino acid sequences shown in SEQ ID NOs: 13-18, or a variant of the heavy chain variable domain having its HC-CDR sequence comprising at most about 5 (e.g., 1, 2, 3, 4, or 5) amino acid substitutions ... The amino acid sequence represented by NOs:30-37, or a variant of the light chain variable domain, contains substitutions of up to about 5 amino acids (e.g., 1, 2, 3, 4, or 5) in its LC-CDR sequence. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0229] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises a) a heavy chain variable domain comprising: HC-CDR1 comprising any of the amino acid sequences shown in SEQ ID NOs: 1-4, HC-CDR2 comprising any of the amino acid sequences shown in SEQ ID NOs: 5-12, and HC-CDR3 comprising any of the amino acid sequences shown in SEQ ID NOs: 13-18, or a variant of the heavy chain variable domain comprising a substitution of up to about 5 (e.g., 1, 2, 3, 4, or 5) amino acids in its HC-CDR sequence; and b) a light chain variable domain comprising: LC-CDR1 comprising any of the amino acid sequences shown in SEQ ID NOs: 19-25, LC-CDR2 comprising any of the amino acid sequences shown in SEQ ID NOs: 26-29, and LC-CDR3 comprising any of the amino acid sequences shown in SEQ ID NOs: 13-18, or a variant of the heavy chain variable domain comprising: HC ... The amino acid sequence represented by NOs:30-37, or a variant of the light chain variable domain, contains substitutions of up to about 5 amino acids (e.g., 1, 2, 3, 4, or 5) in its LC-CDR sequence. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0230] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: a) a heavy chain variable domain comprising: HC-CDR1 comprising any of the amino acid sequences shown in SEQ ID NOs:1-4, HC-CDR2 comprising any of the amino acid sequences shown in SEQ ID NOs:5-12, and HC-CDR3 comprising any of the amino acid sequences shown in SEQ ID NOs:13-18; and b) a light chain variable domain comprising: LC-CDR1 comprising any of the amino acid sequences shown in SEQ ID NOs:19-25, LC-CDR2 comprising any of the amino acid sequences shown in SEQ ID NOs:26-29, and LC-CDR3 comprising any of the amino acid sequences shown in SEQ ID NOs:30-37. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0231] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: a) a heavy chain variable domain comprising: HC-CDR1 comprising any of the amino acid sequences shown in SEQ ID NOs:1-4, HC-CDR2 comprising any of the amino acid sequences shown in SEQ ID NOs:5-12, and HC-CDR3 comprising any of the amino acid sequences shown in SEQ ID NOs:13-18; and b) a light chain variable domain comprising: LC-CDR1 comprising any of the amino acid sequences shown in SEQ ID NOs:19-25, LC-CDR2 comprising any of the amino acid sequences shown in SEQ ID NOs:26-29, and LC-CDR3 comprising any of the amino acid sequences shown in SEQ ID NOs:30-37. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0232] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence SEQ ID NO:1, HC-CDR2 comprising the amino acid sequence SEQ ID NO:5, and HC-CDR3 comprising the amino acid sequence SEQ ID NO:13; and b) a light chain variable domain comprising: LC-CDR1 comprising the amino acid sequence SEQ ID NO:19, LC-CDR2 comprising the amino acid sequence SEQ ID NO:26, and LC-CDR3 comprising the amino acid sequence SEQ ID NO:30. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0233] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence SEQ ID NO:1, HC-CDR2 comprising the amino acid sequence SEQ ID NO:5, and HC-CDR3 comprising the amino acid sequence SEQ ID NO:14; and b) a light chain variable domain comprising: LC-CDR1 comprising the amino acid sequence SEQ ID NO:19, LC-CDR2 comprising the amino acid sequence SEQ ID NO:26, and LC-CDR3 comprising the amino acid sequence SEQ ID NO:31. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0234] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: a) a heavy chain variable domain comprising: HC-CDR1 comprising amino acid sequence SEQ ID NO:2, HC-CDR2 comprising amino acid sequence SEQ ID NO:6, and HC-CDR3 comprising amino acid sequence SEQ ID NO:15; and b) a light chain variable domain comprising: LC-CDR1 comprising amino acid sequence SEQ ID NO:20, LC-CDR2 comprising amino acid sequence SEQ ID NO:27, and LC-CDR3 comprising amino acid sequence SEQ ID NO:32. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0235] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: a) a heavy chain variable domain comprising: HC-CDR1 comprising amino acid sequence SEQ ID NO:2, HC-CDR2 comprising amino acid sequence SEQ ID NO:7, and HC-CDR3 comprising amino acid sequence SEQ ID NO:16; and b) a light chain variable domain comprising: LC-CDR1 comprising amino acid sequence SEQ ID NO:21, LC-CDR2 comprising amino acid sequence SEQ ID NO:27, and LC-CDR3 comprising amino acid sequence SEQ ID NO:33. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0236] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence SEQ ID NO:1, HC-CDR2 comprising the amino acid sequence SEQ ID NO:5, and HC-CDR3 comprising the amino acid sequence SEQ ID NO:17; and b) a light chain variable domain comprising: LC-CDR1 comprising the amino acid sequence SEQ ID NO:19, LC-CDR2 comprising the amino acid sequence SEQ ID NO:26, and LC-CDR3 comprising the amino acid sequence SEQ ID NO:31. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0237] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence SEQ ID NO:3, HC-CDR2 comprising the amino acid sequence SEQ ID NO:8, and HC-CDR3 comprising the amino acid sequence SEQ ID NO:18; and b) a light chain variable domain comprising: LC-CDR1 comprising the amino acid sequence SEQ ID NO:22, LC-CDR2 comprising the amino acid sequence SEQ ID NO:28, and LC-CDR3 comprising the amino acid sequence SEQ ID NO:34. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0238] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence SEQ ID NO:3, HC-CDR2 comprising the amino acid sequence SEQ ID NO:9, and HC-CDR3 comprising the amino acid sequence SEQ ID NO:18; and b) a light chain variable domain comprising: LC-CDR1 comprising the amino acid sequence SEQ ID NO:23, LC-CDR2 comprising the amino acid sequence SEQ ID NO:29, and LC-CDR3 comprising the amino acid sequence SEQ ID NO:35. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0239] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence SEQ ID NO:3, HC-CDR2 comprising the amino acid sequence SEQ ID NO:10, and HC-CDR3 comprising the amino acid sequence SEQ ID NO:18; and b) a light chain variable domain comprising: LC-CDR1 comprising the amino acid sequence SEQ ID NO:22, LC-CDR2 comprising the amino acid sequence SEQ ID NO:28, and LC-CDR3 comprising the amino acid sequence SEQ ID NO:34. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0240] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence SEQ ID NO:4, HC-CDR2 comprising the amino acid sequence SEQ ID NO:11, and HC-CDR3 comprising the amino acid sequence SEQ ID NO:18; and b) a light chain variable domain comprising: LC-CDR1 comprising the amino acid sequence SEQ ID NO:24, LC-CDR2 comprising the amino acid sequence SEQ ID NO:28, and LC-CDR3 comprising the amino acid sequence SEQ ID NO:34. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0241] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence SEQ ID NO:3, HC-CDR2 comprising the amino acid sequence SEQ ID NO:12, and HC-CDR3 comprising the amino acid sequence SEQ ID NO:18; and b) a light chain variable domain comprising: LC-CDR1 comprising the amino acid sequence SEQ ID NO:23, LC-CDR2 comprising the amino acid sequence SEQ ID NO:28, and LC-CDR3 comprising the amino acid sequence SEQ ID NO:36. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0242] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence SEQ ID NO:3, HC-CDR2 comprising the amino acid sequence SEQ ID NO:10, and HC-CDR3 comprising the amino acid sequence SEQ ID NO:18; and b) a light chain variable domain comprising: LC-CDR1 comprising the amino acid sequence SEQ ID NO:25, LC-CDR2 comprising the amino acid sequence SEQ ID NO:28, and LC-CDR3 comprising the amino acid sequence SEQ ID NO:37. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0243] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence SEQ ID NO:1, HC-CDR2 comprising the amino acid sequence SEQ ID NO:5, and HC-CDR3 comprising the amino acid sequence SEQ ID NO:13; and b) a light chain variable domain comprising: LC-CDR1 comprising the amino acid sequence SEQ ID NO:19, LC-CDR2 comprising the amino acid sequence SEQ ID NO:26, and LC-CDR3 comprising the amino acid sequence SEQ ID NO:30. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0244] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence SEQ ID NO:1, HC-CDR2 comprising the amino acid sequence SEQ ID NO:5, and HC-CDR3 comprising the amino acid sequence SEQ ID NO:14; and b) a light chain variable domain comprising: LC-CDR1 comprising the amino acid sequence SEQ ID NO:19, LC-CDR2 comprising the amino acid sequence SEQ ID NO:26, and LC-CDR3 comprising the amino acid sequence SEQ ID NO:31. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0245] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: a) a heavy chain variable domain comprising: HC-CDR1 comprising amino acid sequence SEQ ID NO:2, HC-CDR2 comprising amino acid sequence SEQ ID NO:6, and HC-CDR3 comprising amino acid sequence SEQ ID NO:15; and b) a light chain variable domain comprising: LC-CDR1 comprising amino acid sequence SEQ ID NO:20, LC-CDR2 comprising amino acid sequence SEQ ID NO:27, and LC-CDR3 comprising amino acid sequence SEQ ID NO:32. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0246] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: a) a heavy chain variable domain comprising: HC-CDR1 comprising amino acid sequence SEQ ID NO:2, HC-CDR2 comprising amino acid sequence SEQ ID NO:7, and HC-CDR3 comprising amino acid sequence SEQ ID NO:16; and b) a light chain variable domain comprising: LC-CDR1 comprising amino acid sequence SEQ ID NO:21, LC-CDR2 comprising amino acid sequence SEQ ID NO:27, and LC-CDR3 comprising amino acid sequence SEQ ID NO:33. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0247] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence SEQ ID NO:1, HC-CDR2 comprising the amino acid sequence SEQ ID NO:5, and HC-CDR3 comprising the amino acid sequence SEQ ID NO:17; and b) a light chain variable domain comprising: LC-CDR1 comprising the amino acid sequence SEQ ID NO:19, LC-CDR2 comprising the amino acid sequence SEQ ID NO:26, and LC-CDR3 comprising the amino acid sequence SEQ ID NO:31. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0248] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence SEQ ID NO:3, HC-CDR2 comprising the amino acid sequence SEQ ID NO:8, and HC-CDR3 comprising the amino acid sequence SEQ ID NO:18; and b) a light chain variable domain comprising: LC-CDR1 comprising the amino acid sequence SEQ ID NO:22, LC-CDR2 comprising the amino acid sequence SEQ ID NO:28, and LC-CDR3 comprising the amino acid sequence SEQ ID NO:34. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0249] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence SEQ ID NO:3, HC-CDR2 comprising the amino acid sequence SEQ ID NO:9, and HC-CDR3 comprising the amino acid sequence SEQ ID NO:18; and b) a light chain variable domain comprising: LC-CDR1 comprising the amino acid sequence SEQ ID NO:23, LC-CDR2 comprising the amino acid sequence SEQ ID NO:29, and LC-CDR3 comprising the amino acid sequence SEQ ID NO:35. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0250] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence SEQ ID NO:3, HC-CDR2 comprising the amino acid sequence SEQ ID NO:10, and HC-CDR3 comprising the amino acid sequence SEQ ID NO:18; and b) a light chain variable domain comprising: LC-CDR1 comprising the amino acid sequence SEQ ID NO:22, LC-CDR2 comprising the amino acid sequence SEQ ID NO:28, and LC-CDR3 comprising the amino acid sequence SEQ ID NO:34. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0251] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence SEQ ID NO:4, HC-CDR2 comprising the amino acid sequence SEQ ID NO:11, and HC-CDR3 comprising the amino acid sequence SEQ ID NO:18; and b) a light chain variable domain comprising: LC-CDR1 comprising the amino acid sequence SEQ ID NO:24, LC-CDR2 comprising the amino acid sequence SEQ ID NO:28, and LC-CDR3 comprising the amino acid sequence SEQ ID NO:34. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0252] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence SEQ ID NO:3, HC-CDR2 comprising the amino acid sequence SEQ ID NO:12, and HC-CDR3 comprising the amino acid sequence SEQ ID NO:18; and b) a light chain variable domain comprising: LC-CDR1 comprising the amino acid sequence SEQ ID NO:23, LC-CDR2 comprising the amino acid sequence SEQ ID NO:28, and LC-CDR3 comprising the amino acid sequence SEQ ID NO:36. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0253] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: a) a heavy chain variable domain comprising: HC-CDR1 comprising the amino acid sequence SEQ ID NO:3, HC-CDR2 comprising the amino acid sequence SEQ ID NO:10, and HC-CDR3 comprising the amino acid sequence SEQ ID NO:18; and b) a light chain variable domain comprising: LC-CDR1 comprising the amino acid sequence SEQ ID NO:25, LC-CDR2 comprising the amino acid sequence SEQ ID NO:28, and LC-CDR3 comprising the amino acid sequence SEQ ID NO:37. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0254] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: a heavy chain variable domain (V H ), the V H Contains any of the amino acid sequences shown in SEQ ID NOs:40-61 or variants thereof, said variants having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with any of the amino acid sequences shown in SEQ ID NOs:40-61; and a light chain variable domain (V L ), the V LThe IgG1 comprises any of the amino acid sequences shown in SEQ ID NOs:62-79 or variants thereof, wherein the variants have at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with any of the amino acid sequences shown in SEQ ID NOs:62-79. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0255] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG2 constant region is provided, wherein the anti-MASP2 antibody comprises: a heavy chain variable domain (V H ), the V H Contains any of the amino acid sequences shown in SEQ ID NOs:40-61 or variants thereof, said variants having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with any of the amino acid sequences shown in SEQ ID NOs:40-61; and a light chain variable domain (V L ), the V L The IgG2 comprises any of the amino acid sequences shown in SEQ ID NOs:62-79 or variants thereof, wherein the variants have at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with any of the amino acid sequences shown in SEQ ID NOs:62-79. In some embodiments, the IgG2 is human IgG2. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0256] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG3 constant region is provided, wherein the anti-MASP2 antibody comprises: a heavy chain variable domain (V H ), the V HContains any of the amino acid sequences shown in SEQ ID NOs:40-61 or variants thereof, said variants having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with any of the amino acid sequences shown in SEQ ID NOs:40-61; and a light chain variable domain (V L ), the V L The IgG3 comprises any of the amino acid sequences shown in SEQ ID NOs:62-79 or variants thereof, wherein the variants have at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with any of the amino acid sequences shown in SEQ ID NOs:62-79. In some embodiments, the IgG3 is human IgG3. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0257] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: a heavy chain variable domain (V H ), the V H Contains any of the amino acid sequences shown in SEQ ID NOs:40-61 or variants thereof, said variants having at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with any of the amino acid sequences shown in SEQ ID NOs:40-61; and a light chain variable domain (V L ), the V LThe IgG4 comprises any of the amino acid sequences shown in SEQ ID NOs:62-79 or variants thereof, wherein the variants have at least about 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) sequence identity with any of the amino acid sequences shown in SEQ ID NOs:62-79. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0258] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: a heavy chain variable domain (V H ), the (V) H It contains any of the amino acid sequences shown in SEQ ID NOs:40-61, and a light chain variable domain (V L ), the (V) L The IgG1 comprises any of the amino acid sequences shown in SEQ ID NOs:62-79. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0259] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: a heavy chain variable domain (V H ), the V HContains any of the amino acid sequences shown in SEQ ID NOs:40-61, and a light chain variable domain (V L ), the V L It comprises any of the amino acid sequences shown in SEQ ID NOs:62-79. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0260] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:40 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:40; and V L It comprises the amino acid sequence SEQ ID NO:62 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:62. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0261] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:41 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:41; and V L It comprises the amino acid sequence SEQ ID NO:63 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:63. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0262] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:41 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:41; and V L It comprises the amino acid sequence SEQ ID NO:64 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:64. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0263] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:42 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:42; and V L It comprises the amino acid sequence SEQ ID NO:63 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:63. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0264] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:42 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:42; and V L It comprises the amino acid sequence SEQ ID NO:64 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:64. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0265] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:43 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:43; and V L It comprises the amino acid sequence SEQ ID NO:63 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:63. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0266] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:43 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:43; and V L It comprises the amino acid sequence SEQ ID NO:64 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:64. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0267] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:44 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:44; and V L It comprises the amino acid sequence SEQ ID NO:65 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:65. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0268] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:45 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:45; and V L It comprises the amino acid sequence SEQ ID NO:66 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:66. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0269] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:46 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:46; and V L It comprises the amino acid sequence SEQ ID NO:66 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:66. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0270] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:47 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:47; and V L It comprises the amino acid sequence SEQ ID NO:66 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:66. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0271] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:45 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:45; and V L It comprises the amino acid sequence SEQ ID NO:67 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:67. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0272] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:46 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:46; and V L It comprises the amino acid sequence SEQ ID NO:67 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:67. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0273] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:47 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:47; and V L It comprises the amino acid sequence SEQ ID NO:67 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:67. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0274] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:45 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:45; and V L It comprises the amino acid sequence SEQ ID NO:68 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:68. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0275] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:46 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:46; and V L It comprises the amino acid sequence SEQ ID NO:68 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:68. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0276] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:47 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:47; and V L It comprises the amino acid sequence SEQ ID NO:68 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:68. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0277] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:48 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:48; and V L It comprises the amino acid sequence SEQ ID NO:69 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:69. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0278] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:49 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:49; and V L It comprises the amino acid sequence SEQ ID NO:70 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:70. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0279] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:50 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:50; and V L It comprises the amino acid sequence SEQ ID NO:71 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:71. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0280] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:51 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:51; and V L It comprises the amino acid sequence SEQ ID NO:72 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:72. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0281] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:52 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:52; and V L It comprises the amino acid sequence SEQ ID NO:73 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:73. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0282] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:53 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:53; and V L It comprises the amino acid sequence SEQ ID NO:72 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:72. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0283] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:54 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:54; and V L It comprises the amino acid sequence SEQ ID NO:74 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:74. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0284] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:55 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:55; and V L It comprises the amino acid sequence SEQ ID NO:75 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:75. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0285] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:56 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:56; and V L It comprises the amino acid sequence SEQ ID NO:76 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:76. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0286] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:57 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:57; and V L It comprises the amino acid sequence SEQ ID NO:77 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:77. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0287] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:58 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:58; and V L It comprises the amino acid sequence SEQ ID NO:77 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:77. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0288] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:59 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:59; and V L It comprises the amino acid sequence SEQ ID NO:77 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:77. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0289] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:60 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:60; and V L It comprises the amino acid sequence SEQ ID NO:77 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:77. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0290] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:61 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:61; and V L It comprises the amino acid sequence SEQ ID NO:77 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:77. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0291] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:57 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:57; and V L It comprises the amino acid sequence SEQ ID NO:78 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:78. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0292] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:58 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:58; and V L It comprises the amino acid sequence SEQ ID NO:78 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:78. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0293] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:59 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:59; and V L It comprises the amino acid sequence SEQ ID NO:78 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:78. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0294] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:60 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:60; and V L It comprises the amino acid sequence SEQ ID NO:78 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:78. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0295] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:61 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:61; and V L It comprises the amino acid sequence SEQ ID NO:78 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:78. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0296] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:57 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:57; and V L It comprises the amino acid sequence SEQ ID NO:79 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:79. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0297] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:58 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:58; and V L It comprises the amino acid sequence SEQ ID NO:79 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:79. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0298] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:59 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:59; and V L It comprises the amino acid sequence SEQ ID NO:79 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:79. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0299] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:60 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:60; and V L It comprises the amino acid sequence SEQ ID NO:79 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:79. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0300] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG1 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:61 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:61; and V L It comprises the amino acid sequence SEQ ID NO:79 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:79. In some embodiments, the IgG1 is human IgG1. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:80 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0301] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:40 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:40; and V L It comprises the amino acid sequence SEQ ID NO:62 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:62. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0302] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:41 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:41; and V L It comprises the amino acid sequence SEQ ID NO:63 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:63. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0303] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:41 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:41; and V L It comprises the amino acid sequence SEQ ID NO:64 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:64. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0304] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:42 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:42; and V L It comprises the amino acid sequence SEQ ID NO:63 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:63. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0305] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:42 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:42; and V L It comprises the amino acid sequence SEQ ID NO:64 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:64. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0306] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:43 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:43; and V L It comprises the amino acid sequence SEQ ID NO:63 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:63. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0307] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:43 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:43; and V L It comprises the amino acid sequence SEQ ID NO:64 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:64. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0308] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:44 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:44; and V L It comprises the amino acid sequence SEQ ID NO:65 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:65. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0309] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:45 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:45; and V L It comprises the amino acid sequence SEQ ID NO:66 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:66. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0310] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:46 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:46; and V L It comprises the amino acid sequence SEQ ID NO:66 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:66. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0311] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:47 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:47; and V L It comprises the amino acid sequence SEQ ID NO:66 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:66. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0312] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:45 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:45; and V L It comprises the amino acid sequence SEQ ID NO:67 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:67. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0313] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:46 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:46; and V L It comprises the amino acid sequence SEQ ID NO:67 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:67. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0314] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:47 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:47; and V L It comprises the amino acid sequence SEQ ID NO:67 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:67. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0315] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:45 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:45; and V L It comprises the amino acid sequence SEQ ID NO:68 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:68. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0316] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:46 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:46; and V L It comprises the amino acid sequence SEQ ID NO:68 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:68. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0317] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:47 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:47; and V L It comprises the amino acid sequence SEQ ID NO:68 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:68. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0318] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:48 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:48; and V L It comprises the amino acid sequence SEQ ID NO:69 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:69. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0319] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:49 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:49; and V L It comprises the amino acid sequence SEQ ID NO:70 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:70. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0320] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:50 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:50; and V L It comprises the amino acid sequence SEQ ID NO:71 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:71. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0321] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:51 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:51; and V L It comprises the amino acid sequence SEQ ID NO:72 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:72. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0322] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:52 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:52; and V L It comprises the amino acid sequence SEQ ID NO:73 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:73. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0323] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:53 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:53; and V L It comprises the amino acid sequence SEQ ID NO:72 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:72. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0324] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:54 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:54; and V L It comprises the amino acid sequence SEQ ID NO:74 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:74. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0325] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:55 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:55; and V L It comprises the amino acid sequence SEQ ID NO:75 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:75. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0326] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:56 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:56; and V L It comprises the amino acid sequence SEQ ID NO:76 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:76. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0327] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:57 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:57; and V L It comprises the amino acid sequence SEQ ID NO:77 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:77. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0328] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: V H It comprises the amino acid sequence SEQ ID NO:58 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:58; and V L It comprises the amino acid sequence SEQ ID NO:77 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence SEQ ID NO:77. In some embodiments, the IgG4 is human IgG4. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:82. In some embodiments, the heavy chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:81 and the light chain constant region comprises or is composed of the amino acid sequence SEQ ID NO:83.

[0329] In some embodiments, a full-length anti-MASP2 antibody comprising an IgG4 constant region is provided, wherein the anti-MASP2 antibody comprises: V HIt comprises the amino acid sequence SEQ ID NO:59 or a variant thereof, said variant having at least about 80% sequence identity with the amino acid sequence ...

Claims

1. An isolated antibody that specifically recognizes MASP2, comprising: V H The V H Contains: HC-CDR1, whose amino acid sequence is shown in SEQ ID NO: 1; HC-CDR2, whose amino acid sequence is shown in SEQ ID NO: 5; and HC-CDR3, whose amino acid sequence is shown in SEQ ID NO: 14; and V L The V L It includes: LC-CDR1, whose amino acid sequence is shown in SEQ ID NO: 19; LC-CDR2, whose amino acid sequence is shown in SEQ ID NO: 26; and LC-CDR3, whose amino acid sequence is shown in SEQ ID NO:

31.

2. The isolated antibody specifically recognizing MASP2 according to claim 1, comprising: (i) V H It comprises the amino acid sequence SEQ ID NO: 44 or a variant thereof, said variant having at least 80% sequence identity with the amino acid sequence SEQ ID NO: 44; and V L It contains the amino acid sequence SEQ ID NO: 65 or a variant thereof, said variant having at least 80% sequence identity with the amino acid sequence SEQ ID NO: 65; (ii) V H It comprises the amino acid sequence SEQ ID NO: 45 or a variant thereof, said variant having at least 80% sequence identity with the amino acid sequence SEQ ID NO: 45; and V L It contains the amino acid sequence SEQ ID NO: 66 or a variant thereof, said variant having at least 80% sequence identity with the amino acid sequence SEQ ID NO: 66; (iii) V H It comprises the amino acid sequence SEQ ID NO: 46 or a variant thereof, said variant having at least 80% sequence identity with the amino acid sequence SEQ ID NO: 46; and V L It contains the amino acid sequence SEQ ID NO: 66 or a variant thereof, said variant having at least 80% sequence identity with the amino acid sequence SEQ ID NO: 66; (iv) V H It comprises the amino acid sequence SEQ ID NO: 47 or a variant thereof, said variant having at least 80% sequence identity with the amino acid sequence SEQ ID NO: 47; and V L It contains the amino acid sequence SEQ ID NO: 66 or a variant thereof, said variant having at least 80% sequence identity with the amino acid sequence SEQ ID NO: 66; (v) V H It comprises the amino acid sequence SEQ ID NO: 45 or a variant thereof, said variant having at least 80% sequence identity with the amino acid sequence SEQ ID NO: 45; and V L It contains the amino acid sequence SEQ ID NO: 67 or a variant thereof, said variant having at least 80% sequence identity with the amino acid sequence SEQ ID NO: 67; (vi) V H It comprises the amino acid sequence SEQ ID NO: 46 or a variant thereof, said variant having at least 80% sequence identity with the amino acid sequence SEQ ID NO: 46; and V L It contains the amino acid sequence SEQ ID NO: 67 or a variant thereof, said variant having at least 80% sequence identity with the amino acid sequence SEQ ID NO: 67; (vii) V H It comprises the amino acid sequence SEQ ID NO: 47 or a variant thereof, said variant having at least 80% sequence identity with the amino acid sequence SEQ ID NO: 47; and V L It contains the amino acid sequence SEQ ID NO: 67 or a variant thereof, said variant having at least 80% sequence identity with the amino acid sequence SEQ ID NO: 67; (viii) V H It comprises the amino acid sequence SEQ ID NO: 45 or a variant thereof, said variant having at least 80% sequence identity with the amino acid sequence SEQ ID NO: 45; and V L It contains the amino acid sequence SEQ ID NO: 68 or a variant thereof, said variant having at least 80% sequence identity with the amino acid sequence SEQ ID NO: 68; (ix) V H It comprises the amino acid sequence SEQ ID NO: 46 or a variant thereof, said variant having at least 80% sequence identity with the amino acid sequence SEQ ID NO: 46; and V L It contains the amino acid sequence SEQ ID NO: 68 or a variant thereof, said variant having at least 80% sequence identity with the amino acid sequence SEQ ID NO: 68; or (x) V H It comprises the amino acid sequence SEQ ID NO: 47 or a variant thereof, said variant having at least 80% sequence identity with the amino acid sequence SEQ ID NO: 47; and V L It contains the amino acid sequence SEQ ID NO: 68 or a variant thereof, the variant having at least 80% sequence identity with the amino acid sequence SEQ ID NO:

68.

3. The isolated antibody that specifically recognizes MASP2 according to claim 1 or 2, wherein the antibody comprises an Fc fragment.

4. The isolated antibody that specifically recognizes MASP2 according to claim 3, wherein the antibody is a full-length IgG antibody.

5. The isolated antibody that specifically recognizes MASP2 according to claim 4, wherein the antibody is a full-length IgG1, IgG2, IgG3 or IgG4 antibody.

6. The isolated antibody that specifically recognizes MASP2 according to claim 1 or 2, wherein the antibody is a chimeric or humanized antibody.

7. The isolated antibody that specifically recognizes MASP2 according to claim 1 or 2 is an antigen-binding fragment, wherein the antigen-binding fragment is selected from Fab, Fab', F(ab)'2, Fab'-SH, single-chain antibody, Fv fragment, and double-chain antibody.

8. A nucleic acid molecule encoding an antibody that specifically recognizes MASP2 according to any one of claims 1-7.

9. A carrier comprising the nucleic acid molecule of claim 8.

10. An isolated host cell comprising an antibody that specifically recognizes MASP2 according to any one of claims 1-7, a nucleic acid molecule according to claim 8, or a vector according to claim 9.

11. A method for preparing an antibody that specifically recognizes MASP2, comprising: a) Culture the host cells of claim 10 under conditions that enable effective expression of antibodies that specifically recognize MASP2; and b) Obtain the expressed antibody that specifically recognizes MASP2 from the host cell.

12. A pharmaceutical composition comprising an antibody that specifically recognizes MASP2 according to any one of claims 1-7, a nucleic acid molecule according to claim 8, a carrier according to claim 9, an isolated host cell according to claim 10 or an antibody prepared by the method according to claim 11, and a pharmaceutically acceptable carrier.

13. The use of the antibody of any one of claims 1-7, the nucleic acid molecule of claim 8, the vector of claim 9, the isolated host cell of claim 10, the antibody prepared by the method of claim 11, or the pharmaceutical composition of claim 12 in the preparation of a medicament for treating, preventing, or improving an individual's disease or condition, wherein the disease or condition is selected from membranous glomerulonephritis, lupus nephritis, IgA nephropathy, acute respiratory distress syndrome or systemic inflammatory response syndrome caused by sepsis, atypical hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria, transplant-associated TMA, and acute respiratory distress syndrome or pneumonia caused by coronavirus infection.

14. The use according to claim 13, wherein the coronavirus is SARS-CoV, MERS-CoV and / or SARS-CoV-2.

15. The use according to claim 13 or 14, wherein the drug is administered in combination with another pharmaceutical agent.

16. The use according to claim 15, wherein the other agent is an immunosuppressant.

17. The use according to claim 15, wherein the other agent is an anti-inflammatory drug.

18. The use according to claim 15, wherein the other agent is an analgesic.

19. The use according to claim 15, wherein the other agent is another complement inhibitor.

20. The use according to claim 15, wherein the other agent is a vascular inhibitor.

Images